View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2017	Oct. 27, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	MOLINA HEALTHCARE INC
Entity Central Index Key	0001179929
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Amendment Flag	false
Trading Symbol	moh
Entity Common Stock, Shares Outstanding		57,094,000

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue:
Premium revenue	$ 4,777	$ 4,191	$ 14,165	$ 12,215
Service revenue	130	133	390	408
Premium tax revenue	106	127	331	345
Health insurer fee revenue	0	85	0	251
Investment income and other revenue	18	10	48	29
Total revenue	5,031	4,546	14,934	13,248
Operating expenses:
Medical care costs	4,220	3,748	12,822	10,930
Cost of service revenue	123	119	369	362
General and administrative expenses	383	343	1,227	1,034
Premium tax expenses	106	127	331	345
Health insurer fee expenses	0	55	0	163
Depreciation and amortization	33	36	109	102
Impairment losses	129	0	201	0
Restructuring and separation costs	118	0	161	0
Total operating expenses	5,112	4,428	15,220	12,936
Operating (loss) income	(81)	118	(286)	312
Other expenses, net:
Interest expense	32	26	85	76
Other income, net	0	0	(75)	0
Total other expenses, net	32	26	10	76
(Loss) income before income tax (benefit) expense	(113)	92	(296)	236
Income tax (benefit) expense	(16)	50	(46)	137
Net (loss) income	$ (97)	$ 42	$ (250)	$ 99
Net (loss) income per share:
Basic (in dollars per share)	$ (1.70)	$ 0.77	$ (4.44)	$ 1.79
Diluted (in dollars per share)	$ (1.70)	$ 0.76	$ (4.44)	$ 1.77

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (97)	$ 42	$ (250)	$ 99
Other comprehensive income:
Unrealized investment gain (loss)	1	(3)	2	10
Less: effect of income taxes	1	(2)	1	3
Other comprehensive (loss) income, net of tax	0	(1)	1	7
Comprehensive (loss) income	$ (97)	$ 41	$ (249)	$ 106

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 3,934	$ 2,819
Investments	1,787	1,758
Restricted investments	326	0
Receivables	1,002	974
Income taxes refundable	60	39
Prepaid expenses and other current assets	174	131
Derivative asset	425	267
Total current assets	7,708	5,988
Property, equipment, and capitalized software, net	397	454
Deferred contract costs	97	86
Intangible assets, net	101	140
Goodwill	430	620
Restricted investments	117	110
Deferred income taxes	62	10
Other assets	42	41
Total assets	8,954	7,449
Current liabilities:
Medical claims and benefits payable	2,478	1,929
Amounts due government agencies	1,324	1,202
Accounts payable and accrued liabilities	485	385
Deferred revenue	468	315
Current portion of long-term debt	782	472
Derivative liability	425	267
Total current liabilities	5,962	4,570
Long-term debt	1,317	975
Lease financing obligations	198	198
Deferred income taxes	0	15
Other long-term liabilities	48	42
Total liabilities	7,525	5,800
Stockholders’ equity:
Common stock, $0.001 par value; 150 shares authorized; outstanding: 57 shares at September 30, 2017 and at December 31, 2016	0	0
Preferred stock, $0.001 par value; 20 shares authorized, no shares issued and outstanding	0	0
Additional paid-in capital	870	841
Accumulated other comprehensive loss	(1)	(2)
Retained earnings	560	810
Total stockholders’ equity	1,429	1,649
Total liabilities and stockholders' equity	$ 8,954	$ 7,449

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Common stock, par value (usd per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares outstanding (in shares)	57,000,000	57,000,000
Preferred stock, par value (usd per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Operating activities:
Net (loss) income	$ (250)	$ 99
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	139	135
Impairment losses	201	0
Deferred income taxes	(68)	20
Share-based compensation, including accelerated share-based compensation	38	24
Non-cash restructuring charges	49	0
Amortization of convertible senior notes and lease financing obligations	24	23
Other, net	13	14
Changes in operating assets and liabilities:
Receivables	(28)	(427)
Prepaid expenses and other assets	(53)	(116)
Medical claims and benefits payable	549	168
Amounts due government agencies	122	503
Accounts payable and accrued liabilities	90	1
Deferred revenue	153	157
Income taxes	(22)	32
Net cash provided by operating activities	957	633
Investing activities:
Purchases of investments	(1,896)	(1,444)
Proceeds from sales and maturities of investments	1,538	1,512
Purchases of property, equipment and capitalized software	(85)	(143)
(Increase) decrease in restricted investments held-to-maturity	(10)	4
Net cash paid in business combinations	0	(48)
Other, net	(21)	(12)
Net cash used in investing activities	(474)	(131)
Financing activities:
Proceeds from senior notes offering, net of issuance costs	325	0
Proceeds from borrowings under credit facility	300	0
Proceeds from employee stock plans	11	10
Other, net	(4)	1
Net cash provided by financing activities	632	11
Net increase in cash and cash equivalents	1,115	513
Cash and cash equivalents at beginning of period	2,819	2,329
Cash and cash equivalents at end of period	3,934	2,842
Schedule of non-cash investing and financing activities:
Common stock used for share-based compensation	(21)	(8)
Details of change in fair value of derivatives, net:
Change in fair value of derivatives, net	0	0
Details of business combinations:
Fair value of assets acquired	0	(186)
Fair value of liabilities assumed	0	28
Purchase price amounts accrued/received	0	8
Reversal of amounts advanced to sellers in prior year	0	102
Net cash paid in business combinations	0	(48)
1.125% Call Option
Details of change in fair value of derivatives, net:
Change in fair value of derivatives, net	158	(60)
1.125% Conversion Option
Details of change in fair value of derivatives, net:
Change in fair value of derivatives, net	$ (158)	$ 60

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)	Sep. 30, 2017
1.125% Call Option
Percentage of contractual interest rate on derivative	1.125%
1.125% Conversion Option
Percentage of contractual interest rate on derivative	1.125%

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation Organization and Operations Molina Healthcare, Inc. provides quality managed health care to people receiving government assistance. We offer cost-effective Medicaid-related solutions to meet the health care needs of low-income families and individuals, and to assist government agencies in their administration of the Medicaid program. We have three reportable segments. These segments consist of our Health Plans segment, which constitutes the vast majority of our operations; our Molina Medicaid Solutions segment; and our Other segment. The Health Plans segment consists of health plans operating in 12 states and the Commonwealth of Puerto Rico. As of September 30, 2017, these health plans served approximately 4.5 million members eligible for Medicaid, Medicare, and other government-sponsored health care programs for low-income families and individuals. This membership includes Affordable Care Act Marketplace (Marketplace) members, most of whom receive government premium subsidies. The health plans are operated by our respective wholly owned subsidiaries in those states, each of which is licensed as a health maintenance organization (HMO). Our health plans’ state Medicaid contracts generally have terms of three to four years. These contracts typically contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Our health plan subsidiaries have generally been successful in retaining their contracts, but such contracts are subject to risk of loss when a state issues a new request for proposal (RFP) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may be subject to non-renewal. In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled (ABD); and regions or service areas. The Molina Medicaid Solutions segment provides support to state government agencies in the administration of their Medicaid programs, including business processing, information technology development and administrative services. The Other segment includes primarily our Pathways behavioral health and social services provider, and corporate amounts not allocated to other reportable segments. Recent Developments — Health Plans Segment Illinois Health Plan. In August 2017, Molina Healthcare of Illinois, Inc. was awarded a statewide Medicaid managed care contract by the Illinois Department of Healthcare and Family Services. This Medicaid contract further integrates behavioral health and physical health by combining the State’s three current managed care programs into one program. The contract begins January 1, 2018, for four years with options to renew annually for up to four additional years. Mississippi Health Plan. In June 2017, Molina Healthcare of Mississippi, Inc. was awarded a Medicaid Coordinated Care Contract for the statewide administration of the Mississippi Coordinated Access Network (MississippiCAN). The operational start date for the program is currently scheduled for October 1, 2018, pending the completion of a readiness review. The initial term of the contract is through June 2020, with options to renew annually for up to two additional years. Washington Health Plan. In May 2017, Molina Healthcare of Washington, Inc. was selected by the Washington State Health Care Authority to negotiate and enter into managed care contracts for the North Central region of the state’s Apple Health Integrated Managed Care Program. The start date for the new contract is scheduled for January 1, 2018. Terminated Medicare Acquisition. In August 2016, we entered into agreements with each of Aetna Inc. and Humana Inc. to acquire certain assets related to their Medicare Advantage business. The transaction was subject to closing conditions including the completion of the proposed acquisition of Humana by Aetna (the Aetna-Humana Merger). In January 2017, the U.S. District Court for the District of Columbia granted the request for relief made by the U.S. Department of Justice in its civil antitrust lawsuit against Aetna and Humana, to prohibit the Aetna-Humana Merger. In February 2017, our agreements with each of Aetna and Humana were terminated by the parties pursuant to the terms of the agreements. Under the termination agreements, we received an aggregate termination fee of $75 million from Aetna and Humana in the first quarter of 2017, which is reported in “Other income, net” in the accompanying consolidated statements of operations. New York Health Plan. In August 2016, we closed on our acquisition of the outstanding equity interests of Today’s Options of New York, Inc., which now operates as Molina Healthcare of New York, Inc. The purchase price allocation was completed, and the final purchase price adjustments were recorded, in the first quarter of 2017. Such adjustments were insignificant, and the final cash purchase price was $38 million. Impairment Losses Molina Medicaid Solutions segment. In the third quarter of 2017, we recorded a non-cash goodwill impairment loss of $28 million. See Note 10, “Impairment Losses.” Other segment. In the third quarter of 2017, we recorded a non-cash goodwill impairment loss of $101 million for our Pathways subsidiary. In the second quarter of 2017, we recorded non-cash goodwill and intangible assets impairment losses of $72 million, primarily for our Pathways subsidiary. See Note 10, “Impairment Losses.” Consolidation and Interim Financial Information The consolidated financial statements include the accounts of Molina Healthcare, Inc., its subsidiaries, and variable interest entities (VIEs) in which Molina Healthcare, Inc. is considered to be the primary beneficiary. Such VIEs are insignificant to our consolidated financial position and results of operations. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the current interim period are not necessarily indicative of the results for the entire year ending December 31, 2017. The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December 31, 2016. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in the December 31, 2016 audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our December 31, 2016 audited consolidated financial statements.

Significant Accounting Policies

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Significant Accounting Policies

Certain of our significant accounting policies are discussed within the note to which they specifically relate.

Revenue Recognition – Health Plans Segment

Premium revenue is fixed in advance of the periods covered and, except as described below, is not generally subject to significant accounting estimates. Premium revenues are recognized in the month that members are entitled to receive health care services, and premiums collected in advance are deferred. Certain components of premium revenue are subject to accounting estimates and fall into two broad categories discussed in further detail below: 1) “Contractual Provisions That May Adjust or Limit Revenue or Profit;” and 2) “Quality Incentives.”

Contractual Provisions That May Adjust or Limit Revenue or Profit

Medicaid

Medical Cost Floors (Minimums), and Medical Cost Corridors: A portion of our premium revenue may be returned if certain minimum amounts are not spent on defined medical care costs. In the aggregate, we recorded a liability under the terms of such contract provisions of $119 million and $272 million at September 30, 2017 and December 31, 2016, respectively, to “Amounts due government agencies.” Approximately $82 million and $244 million of the liability accrued at September 30, 2017 and December 31, 2016, respectively, relates to our participation in Medicaid Expansion programs.

In certain circumstances, our health plans may receive additional premiums if amounts spent on medical care costs exceed a defined maximum threshold. Receivables relating to such provisions were insignificant at September 30, 2017 and December 31, 2016.

Profit Sharing and Profit Ceiling: Our contracts with certain states contain profit-sharing or profit ceiling provisions under which we refund amounts to the states if our health plans generate profit above a certain specified percentage. In some cases, we are limited in the amount of administrative costs that we may deduct in calculating the refund, if any. Liabilities for profits in excess of the amount we are allowed to retain under these provisions were insignificant at September 30, 2017 and December 31, 2016.

Retroactive Premium Adjustments: State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we must adjust our premium revenue in the period in which we learn of the adjustment, rather than in the months of service to which the retroactive adjustment applies.

Medicare

Risk Adjustment: Our Medicare premiums are subject to retroactive increase or decrease based on the health status of our Medicare members (measured as a member risk score). We estimate our members’ risk scores and the related amount of Medicare revenue that will ultimately be realized for the periods presented based on our knowledge of our members’ health status, risk scores and the Centers for Medicare & Medicaid Services (CMS) practices. Consolidated balance sheet amounts related to anticipated Medicare risk adjustment premiums and Medicare Part D settlements were insignificant at September 30, 2017 and December 31, 2016.

Minimum MLR: Additionally, federal regulations have established a minimum annual medical loss ratio (Minimum MLR) of 85% for Medicare. The medical loss ratio represents medical costs as a percentage of premium revenue. Federal regulations define what constitutes medical costs and premium revenue. If the Minimum MLR is not met, we may be required to pay rebates to the federal government. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of operations.

Marketplace

Premium Stabilization Programs: The Affordable Care Act (ACA) established Marketplace premium stabilization programs effective January 1, 2014. These programs, commonly referred to as the “3R’s,” include a permanent risk adjustment program, a transitional reinsurance program, and a temporary risk corridor program. We record receivables or payables related to the 3R programs and the Minimum MLR when the amounts are reasonably estimable as described below, and, for receivables, when collection is reasonably assured. Our receivables (payables) for each of these programs, as of the dates indicated, were as follows:



	September 30, 2017								December 31, 2016
	Current Benefit Year			Prior Benefit Years		Total			December 31, 2016

	(In millions)
Risk adjustment	$	(655	)	$	—	$	(655	)	$	(522	)
Reinsurance	—			10		10			55
Risk corridor	—			—		—			(1		)
Minimum MLR	(27		)	—		(27		)	(1		)

•

Risk adjustment: Under this permanent program, our health plans’ composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk transfer payment into the pool if their composite risk scores are below the average risk score, and will receive a risk transfer payment from the pool if their composite risk scores are above the average risk score. We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of operations.


•	Reinsurance: This program was designed to provide reimbursement to insurers for high cost members and ended December 31, 2016; we expect to settle the outstanding receivable balance in 2017.


•	Risk corridor: This program was intended to limit gains and losses of insurers by comparing allowable costs to a target amount as defined by CMS, and ended December 31, 2016; all outstanding balances were settled as of September 30, 2017.

Additionally, the ACA established a Minimum MLR of 80% for the Marketplace. The medical loss ratio represents medical costs as a percentage of premium revenue. Federal regulations define what constitutes medical costs and premium revenue. If the Minimum MLR is not met, we may be required to pay rebates to our Marketplace policyholders. Each of the 3R programs is taken into consideration when computing the Minimum MLR. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of operations.

Quality Incentives

At several of our health plans, revenue ranging from approximately 1% to 3% of certain health plan premiums is earned only if certain performance measures are met.

The following table quantifies the quality incentive premium revenue recognized for the periods presented, including the amounts earned in the periods presented and prior periods. Although the reasonably possible effects of a change in estimate related to quality incentive premium revenue as of September 30, 2017 are not known, we have no reason to believe that the adjustments to prior years noted below are not indicative of the potential future changes in our estimates as of September 30, 2017.



	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
	(Dollars in millions)
Maximum available quality incentive premium - current period	$	36		$	33		$	113		$	114
Quality incentive premium revenue recognized in current period:
Earned current period	$	24		$	26		$	72		$	80
Earned prior periods	3			—			9			54
Total	$	27		$	26		$	81		134

Quality incentive premium revenue recognized as a percentage of total premium revenue	0.6		%	0.6		%	0.6		%	1.1		%

Income Taxes

The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S. federal statutory rate primarily because of state taxes, nondeductible expenses such as the Health Insurer Fee (HIF), goodwill impairment, certain compensation, and other general and administrative expenses. The effective tax rate was not impacted by HIF in 2017 given the 2017 HIF moratorium.

The effective tax rate may be subject to fluctuations during the year, particularly as a result of the level of pretax earnings, and also as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including factors such as the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.

Premium Deficiency Reserves on Loss Contracts

We assess the profitability of our medical care policies to identify groups of contracts where current operating results or forecasts indicate probable future losses. If anticipated future variable costs exceed anticipated future premiums and investment income, a premium deficiency reserve is recognized. We assume a full-year CSR reconciliation (see further information below) in the premium deficiency reserve calculation for the Marketplace program. We recorded a premium deficiency reserve to “Medical claims and benefits payable” on our accompanying consolidated balance sheets relating to our Marketplace program of $30 million as of December 31, 2016, which increased to $100 million as of June 30, 2017, and then decreased to $70 million as of September 30, 2017. If a nine-month CSR reconciliation had been included in the computation rather than a full year, the premium deficiency reserve would have increased by $55 million, to $125 million as of September 30, 2017. The theoretical $55 million increase to the premium deficiency reserve is less than the potential fourth quarter 2017 impact described below, or $85 million, because such adjustment only recognizes the potential CSR impact to the extent it would have created a deficiency in premiums at September 30, 2017.

Marketplace Cost Share Reduction (CSR) Update

Our third quarter results do not include any potential impact from the October 12, 2017, direction to Centers for Medicare and Medicaid Services (CMS) from Acting Department of Health and Human Services Secretary Hargan to cease payment of Marketplace CSR subsidies. At September 30, 2017, we had a total of approximately $220 million in excess CSR subsidies, recorded as a payable to CMS. This payable represents the extent to which payments received by us from CMS exceeded our estimate of the actual cost of member subsidies incurred by us through September 30, 2017.

We expect to incur approximately $85 million in unreimbursed expense associated with the cessation of CSR subsidies in the fourth quarter of 2017. It has been the practice of CMS to perform a reconciliation on an annual basis of CSR subsidies paid to all health plans against the actual costs incurred by the health plans. Were such a reconciliation to be performed for the full calendar year of 2017—consistent with past practice—we would be able to offset nearly all of the $85 million expense incurred in the fourth quarter against the excess amounts received prior to September 30, 2017. However, should CMS transition to a nine month reconciliation period ending September 30, 2017—the last month for which CSR subsidies have been paid—the absence of CSR subsidy reimbursement would reduce income before income tax expense by approximately $85 million in the fourth quarter of 2017.

Recent Accounting Pronouncements

Goodwill Impairment. In January 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2017-04, Simplifying the Test for Goodwill Impairment, which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment loss. Instead, an impairment loss is measured as the excess of the carrying amount of the reporting unit, including goodwill, over the fair value of the reporting unit. ASU 2017-04 is effective beginning January 1, 2020; we early adopted ASU 2017-04 as of June 30, 2017, in connection with the interim assessment of our Pathways subsidiary. See further discussion at Note 10, “Impairment Losses.”

Restricted Cash. In November 2016, the FASB issued ASU 2016-18, Restricted Cash, which will require us to include in our consolidated statements of cash flows the balances of cash, cash equivalents, restricted cash and restricted cash equivalents. When these items are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the totals in the statement of cash flows to the related captions in the balance sheet. Transfers between cash and cash equivalents and restricted cash and restricted cash equivalents will no longer be presented in the statement of cash flows. ASU 2016-18 is effective beginning January 1, 2018; early adoption is permitted. We are currently evaluating the changes that will be required in our consolidated statements of cash flows.

Stock Compensation. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, which amends ASC Topic 718, Compensation – Stock Compensation. ASU 2016-09 simplifies several aspects of accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, statutory tax and classification in the statement of cash flows. We adopted ASU 2016-09 in the first quarter of 2017; such adoption did not significantly impact our consolidated financial statements. In addition, the prior period presentation in the statement of cash flows was not adjusted because such adjustments were insignificant.

Leases. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), as modified by ASU 2017-03, Transition and Open Effective Date Information. Under ASU 2016-02, an entity will be required to recognize assets and liabilities for the rights and obligations created by leases on the entity’s balance sheet for both finance and operating leases. For leases with a term of 12 months or less, an entity can elect to not recognize lease assets and lease liabilities and expense the lease over a straight-line basis for the term of the lease. ASU 2016-02 will require new disclosures that depict the amount, timing, and uncertainty of cash flows pertaining to an entity’s leases. ASU 2016-02 is effective for us beginning January 1, 2019, and must be adopted using a modified retrospective approach for annual and interim periods beginning after December 15, 2018. Early adoption is permitted. Under this guidance, we will record assets and liabilities relating primarily to our long-term office leases. We are evaluating the effect to our consolidated financial statements.

Revenue Recognition. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). We intend to adopt this standard and the related modifications on January 1, 2018, using the modified retrospective approach. Under this approach, the cumulative effect of initially applying the guidance will be reflected as an adjustment to beginning retained earnings.

We have determined that the insurance contracts of our Health Plans segment, which segment constitutes the vast majority of our operations, are excluded from the scope of Topic 606 because the recognition of revenue under these contracts is dictated by other accounting standards governing insurance contracts.

For our Molina Medicaid Solutions segment, we have reevaluated our earlier assessment and determined that revenue for contracts that include design, development and implementation of Medicaid managed care systems shall be deferred until the system ‘go-live’ date, and then generally recognized on a straight-line basis over the hosting period. This approach is consistent with the FASB/IASB Joint Transition Resource Group for Revenue Recognition view for entities that provide software as a service solution, and similar to our historical revenue recognition methodology. We are continuing to evaluate the existence of customers’ rights with regard to renewal options and whether such rights may constitute separate performance obligations. We expect that cost of service revenue will generally be recognized in a manner consistent with the corresponding revenue recognition.

We believe the cumulative adjustment to retained earnings associated with the adoption of Topic 606 effective January 1, 2018, will be insignificant for both our Molina Medicaid Solutions and Other segments.

Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (SEC) did not have, or are not believed by management to have, a significant impact on our present or future consolidated financial statements.

Net (Loss) Income per Share

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Net (Loss) Income per Share

The following table sets forth the calculation of basic and diluted net (loss) income per share:



	Three Months Ended September 30,					Nine Months Ended September 30,
	2017			2016		2017			2016
	(In millions, except net income per share)
Numerator:
Net (loss) income	$	(97	)	$	42	$	(250	)	$	99
Denominator:
Denominator for basic net (loss) income per share	57			56		56			55
Effect of dilutive securities:
1.125% Warrants ⁽¹⁾	—			—		—			1
Denominator for diluted net (loss) income per share	57			56		56			56

Net (loss) income per share: ⁽²⁾
Basic	$	(1.70	)	$	0.77	$	(4.44	)	$	1.79
Diluted	$	(1.70	)	$	0.76	$	(4.44	)	$	1.77

Potentially dilutive common shares excluded from calculations:
1.125% Warrants⁽¹⁾	2			—		2			—
1.625% Notes⁽¹⁾	1			—		—			—

______________________________

(1)

For more information regarding the 1.125% Warrants, refer to Note 9, “Stockholders' Equity.” For more information regarding the 1.625% Notes, refer to Note 7, “Debt.” The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. Potentially dilutive common shares were not included in the computation of diluted net loss per share in the three and nine months ended September 30, 2017, because to do so would have been anti-dilutive.


(2)	Source data for calculations in thousands.

Fair Value Measurements

9 Months Ended

Sep. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurements

We consider the carrying amounts of cash, cash equivalents and other current assets and current liabilities (not including derivatives and the current portion of long-term debt) to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to the three-tier fair value hierarchy. For a description of the methods and assumptions that we use to a) estimate the fair value; and b) determine the classification according to the fair value hierarchy for each financial instrument, see Note 5, “Fair Value Measurements,” in our 2016 Annual Report on Form 10-K.

Derivative financial instruments include the 1.125% Call Option derivative asset and the 1.125% Conversion Option derivative liability. These derivatives are not actively traded and are valued based on an option pricing model that uses observable and unobservable market data for inputs. Significant market data inputs used to determine fair value as of September 30, 2017, included the price of our common stock, the time to maturity of the derivative instruments, the risk-free interest rate, and the implied volatility of our common stock. As described further in Note 8, “Derivatives,” the 1.125% Call Option asset and the 1.125% Conversion Option liability were designed such that changes in their fair values would offset, with minimal impact to the consolidated statements of operations. Therefore, the sensitivity of changes in the unobservable inputs to the option pricing model for such instruments is mitigated.

The net changes in fair value of Level 3 financial instruments were insignificant to our results of operations for the nine months ended September 30, 2017.

Our financial instruments measured at fair value on a recurring basis at September 30, 2017, were as follows:



	Total		Quoted Market Prices (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	(In millions)
Corporate debt securities	$	1,162	$	—	$	1,162	$	—
Government-sponsored enterprise securities (GSEs)	220		220		—		—
Municipal securities	131		—		131		—
Asset-backed securities	125		—		125		—
U.S. treasury notes	121		121		—		—
Certificates of deposit	28		—		28		—
Subtotal - current investments	1,787		341		1,446		—
Corporate debt securities	229		—		229		—
U.S. treasury notes	97		97		—		—
Subtotal - current restricted investments	326		97		229		—
1.125% Call Option derivative asset	425		—		—		425
Total assets	$	2,538	$	438	$	1,675	$	425

1.125% Conversion Option derivative liability	$	425	$	—	$	—	$	425
Total liabilities	$	425	$	—	$	—	$	425

Our financial instruments measured at fair value on a recurring basis at December 31, 2016, were as follows:



	Total		Quoted Market Prices (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	(In millions)
Corporate debt securities	$	1,179	$	—	$	1,179	$	—
GSEs	231		231		—		—
Municipal securities	142		—		142		—
Asset-backed securities	69		—		69		—
U.S. treasury notes	84		84		—		—
Certificates of deposit	53		—		53		—
Subtotal - current investments	1,758		315		1,443		—
1.125% Call Option derivative asset	267		—		—		267
Total assets	$	2,025	$	315	$	1,443	$	267

1.125% Conversion Option derivative liability	$	267	$	—	$	—	$	267
Total liabilities	$	267	$	—	$	—	$	267

There were no current restricted investments as of December 31, 2016.

Fair Value Measurements – Disclosure Only

The carrying amounts and estimated fair values of our senior notes are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets. The carrying amount and estimated fair value of the amount due under our Credit Facility is classified as a Level 3 financial instrument, because certain inputs used to determine its fair value are not observable. As of September 30, 2017, the carrying value of the amount due under the Credit Facility approximates it fair value because of the recency of this borrowing during the third quarter of 2017.



	September 30, 2017				December 31, 2016
	Carrying Value		Fair Value		Carrying Value		Fair Value
	(In millions)
5.375% Notes	$	692	$	726	$	691	$	714
1.125% Convertible Notes	489		927		471		792
4.875% Notes	325		324		—		—
Credit Facility	300		300		—		—
1.625% Convertible Notes	292		373		284		344
	$	2,098	$	2,650	$	1,446	$	1,850

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Investments

9 Months Ended

Sep. 30, 2017

Investments, Debt and Equity Securities [Abstract]

Investments

Available-for-Sale Investments

We consider all of our investments classified as current assets (including restricted investments) to be available-for-sale. Certain of our senior notes, as further discussed in Note 7, “Debt,” contain a limitation on the use of proceeds which required us to deposit the net proceeds from their issuance into a segregated deposit account, a current asset reported as “Restricted investments” in the accompanying consolidated balance sheets. Such proceeds, while restricted as to their use and held in a segregated deposit account, are available-for-sale based upon our contractual liquidity requirements.

The following tables summarize our investments as of the dates indicated:



	September 30, 2017
	Amortized		Gross Unrealized				Estimated Fair
	Cost		Gains		Losses		Value
	(In millions)
Corporate debt securities	$	1,162	$	1	$	1	$	1,162
GSEs	221		—		1		220
Municipal securities	132		—		1		131
Asset-backed securities	125		—		—		125
U.S. treasury notes	121		—		—		121
Certificates of deposit	28		—		—		28
Subtotal - current investments	1,789		1		3		1,787
Corporate debt securities	229		—		—		229
U.S. treasury notes	97		—		—		97
Subtotal - current restricted investments	326		—		—		326
	$	2,115	$	1	$	3	$	2,113



	December 31, 2016
	Amortized		Gross Unrealized				Estimated Fair
	Cost		Gains		Losses		Value
	(In millions)
Corporate debt securities	$	1,180	$	1	$	2	$	1,179
GSEs	232		—		1		231
Municipal securities	143		—		1		142
Asset-backed securities	69		—		—		69
U.S. treasury notes	84		—		—		84
Certificates of deposit	53		—		—		53
	$	1,761	$	1	$	4	$	1,758

There were no current restricted investments as of December 31, 2016.

The contractual maturities of our available-for-sale investments as of September 30, 2017 are summarized below:



	Amortized Cost		Estimated Fair Value
	(In millions)
Due in one year or less	$	1,154	$	1,153
Due after one year through five years	944		943
Due after five years through ten years	17		17
	$	2,115	$	2,113

Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains and losses for the three and nine months ended September 30, 2017 and 2016 were insignificant.

We have determined that unrealized losses at September 30, 2017 and December 31, 2016, are temporary in nature, because the change in market value for these securities has resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.

The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of September 30, 2017:



	In a Continuous Loss Position for Less than 12 Months					In a Continuous Loss Position for 12 Months or More
	Estimated Fair Value		Unrealized Losses		Total Number of Positions	Estimated Fair Value		Unrealized Losses		Total Number of Positions
	(Dollars in millions)
Corporate debt securities	$	783	$	1	314	$	—	$	—	—
GSEs	—		—		—	58		1		20
Municipal securities	97		1		116	—		—		—
	$	880	$	2	430	$	58	$	1	20



	In a Continuous Loss Position for Less than 12 Months					In a Continuous Loss Position for 12 Months or More
	Estimated Fair Value		Unrealized Losses		Total Number of Positions	Estimated Fair Value		Unrealized Losses		Total Number of Positions
	(Dollars in millions)
Corporate debt securities	$	542	$	2	378	$	—	$	—	—
GSEs	198		1		73	—		—		—
Municipal securities	101		1		129	—		—		—
	$	841	$	4	580	$	—	$	—	—

Held-to-Maturity Investments

Pursuant to the regulations governing our Health Plans segment subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in certificates of deposit and U.S. treasury securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulation in the various states in which we operate, or as needed in the event of insolvency of capitated providers. Therefore, such investments are reported as non-current “Restricted investments” in the accompanying consolidated balance sheets. We have the ability to hold these restricted investments until maturity, and as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates.

The contractual maturities of our held-to-maturity restricted investments, which are carried at amortized cost, which approximates fair value, as of September 30, 2017 are summarized below:



	Amortized Cost		Estimated Fair Value
	(In millions)
Due in one year or less	$	100	$	100
Due after one year through five years	17		17
	$	117	$	117

Medical Claims and Benefits Payable

9 Months Ended

Sep. 30, 2017

Other Liabilities Disclosure [Abstract]

Medical Claims and Benefits Payable

The following table provides the details of our medical claims and benefits payable (including amounts payable for the provision of long-term services and supports, or LTSS) as of the dates indicated:



	September 30, 2017		December 31, 2016
	(In millions)
Fee-for-service claims incurred but not paid (IBNP)	$	1,681	$	1,352
Pharmacy payable	125		112
Capitation payable	57		37
Other	615		428
	$	2,478	$	1,929

“Other” medical claims and benefits payable include amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of operations. Non-risk provider payables amounted to $403 million and $225 million as of September 30, 2017 and December 31, 2016, respectively.

Reinsurance recoverables of $16 million and $72 million as of September 30, 2017 and 2016, respectively, are included in “Receivables” in the accompanying consolidated balance sheets.

The following table presents the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for “Components of medical care costs related to: Prior periods” represent the amounts by which our original estimate of medical claims and benefits payable at the beginning of the period were less (more) than the actual amount of the liability based on information (principally the payment of claims) developed since that liability was first reported.



	Nine Months Ended September 30,
	2017			2016
	(Dollars in millions)
Medical claims and benefits payable, beginning balance	$	1,929		$	1,685
Components of medical care costs related to:
Current period	12,813			11,120
Prior periods	9			(190		)
Total medical care costs	12,822			10,930

Change in non-risk provider payables	172			70

Payments for medical care costs related to:
Current period	10,944			9,536
Prior periods	1,501			1,278
Total paid	12,445			10,814
Medical claims and benefits payable, ending balance	$	2,478		$	1,871
Benefit from prior period as a percentage of:
Balance at beginning of period	(0.5		)%	11.3		%
Premium revenue, trailing twelve months	—		%	1.2		%
Medical care costs, trailing twelve months	(0.1		)%	1.3		%

Assuming that our initial estimate of IBNP is accurate, we believe that amounts ultimately paid would generally be between 8% and 10% less than the IBNP liability recorded at the end of the period as a result of the inclusion in that liability of the provision for adverse claims deviation and the accrued cost of settling those claims. Because the amount of our initial liability is merely an estimate (and therefore not perfectly accurate), we will always experience variability in that estimate as new information becomes available with the passage of time. Therefore, there can be no assurance that amounts ultimately paid out will fall within the range of 8% to 10% lower than the liability that was initially recorded. Furthermore, because our initial estimate of IBNP is derived from many factors, some of which are qualitative in nature rather than quantitative, we are seldom able to assign specific values to the reasons for a change in estimate—we only know when the circumstances for any one or more factors are out of the ordinary.

The differences between our original estimates and the amounts ultimately paid out (or now expected to be ultimately paid out) for the most part related to IBNP. While many related factors working in conjunction with one another serve to determine the accuracy of our estimates, we are seldom able to quantify the impact that any single factor has on a change in estimate. In addition, given the variability inherent in the reserving process, we will only be able to identify specific factors if they represent a significant departure from expectations. As a result, we do not expect to be able to fully quantify the impact of individual factors on changes in estimates.

Prior period development of our estimate as of December 31, 2016, through September 30, 2017, was unfavorable by $9 million, which is substantially less than the favorable prior period development of $190 million we recognized for the same period in the prior year. Further, the unfavorable development through September 30, 2017, was less than the 8% to 10% favorable development we typically expect.

We believe that the most significant uncertainties surrounding our IBNP estimates at September 30, 2017 are as follows:


•	At our Florida health plan, the inventory of unpaid claims increased significantly during the first two quarters of 2017, and then dropped in the third quarter. For this reason, the timing between the dates of service and the dates claims are paid will be impacted, making our liability estimates subject to more than the usual amount of uncertainty.


•	At our Illinois health plan, in 2017 we paid a large number of claims that had previously been denied and were subsequently disputed by providers. We have also established a liability for additional expected claims resulting from provider disputes. This has created some distortion in the claims payment patterns, making our liability estimates subject to more than the usual amount of uncertainty.


•	At our California health plan, we adjusted our inpatient authorization process. As a result, due to the expected increase in authorized inpatient stays, our liability estimates are subject to more than the usual amount of uncertainty.

•

At our Illinois and New York health plans, we implemented a new process for increased quality review of claims payments. While we do not anticipate this new process will impact the percentage of claims paid within the timely turnaround requirements, we believe it will have a minor impact on the timing of some paid claims. For this reason, our liability estimates in these two health plans are subject to more than the usual amount of uncertainty.


•	At our Puerto Rico health plan, Hurricane Maria had a significant impact on both utilization of services and our ability to process claims payments in Puerto Rico. For these reasons, we believe our liability estimates are subject to more than the usual amount of uncertainty.

Debt

9 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Debt

Substantially all of our debt is held at the parent, which is reported in the Other segment. The following table summarizes our outstanding debt obligations and their classification in the accompanying consolidated balance sheets (in millions):



	September 30, 2017			December 31, 2016
Current portion of long-term debt:
1.125% Convertible Notes, net of unamortized discount	$	494		$	477
1.625% Convertible Notes, net of unamortized premium and discount	293			—
Lease financing obligations	1			1
Debt issuance costs	(6		)	(6		)
	782			472
Non-current portion of long-term debt:
5.375% Notes	700			700
4.875% Notes	330			—
Credit Facility	300			—
1.625% Convertible Notes, net of unamortized premium and discount	—			286
Debt issuance costs	(13		)	(11		)
	1,317			975
Lease financing obligations	198			198
	$	2,297		$	1,645

4.875% Notes due 2025

On June 6, 2017, we completed the private offering of $330 million aggregate principal amount of senior notes (4.875% Notes) due June 15, 2025, unless earlier redeemed. Interest on the 4.875% Notes is payable semiannually in arrears on June 15 and December 15. According to their terms, the guarantees under the 4.875% Notes mirror those of the Credit Facility, defined and described below. See Note 16, “Supplemental Condensed Consolidating Financial Information,” for more information on the guarantors. The 4.875% Notes contain customary non-financial covenants and change of control provisions.

The 4.875% Notes contain a limitation on the use of proceeds which required us to deposit the net proceeds from their issuance into a segregated deposit account, a current asset reported as “Restricted investments” in our consolidated balance sheets. These funds may be used by us as follows:


•	On or prior to August 20, 2018, to:


◦	Redeem, repurchase, repay, tender for, or acquire for value all or any portion of our 1.625% Convertible Notes, defined and discussed further below, or to satisfy the cash portion of any consideration due upon any conversion of the 1.625% Convertible Notes; and/or


◦	Pay any interest due on all or any portion of the 4.875% Notes.


•	On or after August 20, 2018, to repurchase all or any portion of the 1.625% Convertible Notes that we are obligated to repurchase; and


•	Subsequent to August 20, 2018 (or such earlier date in the event that there are no longer any 1.625% Convertible Notes outstanding), in any other manner not otherwise prohibited in the indenture governing the 4.875% Notes.

5.375% Notes due 2022

We have outstanding $700 million aggregate principal amount of senior notes (5.375% Notes) due November 15, 2022, unless earlier redeemed. According to their terms, the guarantees under the 5.375% Notes mirror those of the Credit Facility, defined and described below. See Note 16, “Supplemental Condensed Consolidating Financial Information,” for more information on the guarantors.

Credit Facility

In January 2017, we entered into an amended unsecured $500 million revolving credit facility (Credit Facility), referred to as the First Amendment. The Credit Facility has a term of five years and all amounts outstanding will be due and payable on January 31, 2022. As of September 30, 2017, $300 million was outstanding under the Credit Facility, and we were in compliance with all financial and non-financial covenants under the Credit Facility. Also as of September 30, 2017, outstanding letters of credit amounting to $6 million reduced our remaining borrowing capacity under the Credit Facility to $194 million.

In addition to increasing amounts available to borrow under the Credit Facility and extending its term, the First Amendment provided that all guarantors immediately prior to January 3, 2017, other than Molina Information Systems, LLC, d/b/a Molina Medicaid Solutions, Molina Pathways, LLC, and Pathways Health and Community Support LLC, were automatically and unconditionally released from their obligations as guarantors of the Credit Facility and the 5.375% Notes.

The Credit Facility contains customary non-financial and financial covenants, including a net leverage ratio and an interest coverage ratio. In February 2017, we entered into a second amendment to the Credit Facility (the Second Amendment) which modified the Credit Facility’s definition of the earnings measure used in the financial covenant computations to a) allow us to receive credit for risk corridor payments owed to, but not received or accrued by us during 2016; and b) account for the difference between the amount of actual risk transfer payments made or accrued by us during 2016, and the amount of risk transfer payments that would have been due under the federal government’s proposed 2018 risk adjustment payment transfer formula.

In May 2017, we entered into a third amendment to the Credit Facility (the Third Amendment) which modified the Credit Facility’s definition of specified cash, to permit cash that is either subject to customary escrow arrangements or held in a segregated account to be netted from the Credit Facility’s consolidated net leverage ratio if the use of the cash is limited to the repayment of other indebtedness. The Third Amendment also adds a carve-out to the Credit Facility’s negative pledge covenant to allow for the escrow arrangements and segregated accounts.

In August 2017, we entered into a fourth amendment to the Credit Facility (the Fourth Amendment). The Fourth Amendment modified the definition of consolidated adjusted EBITDA to permit the add-back of certain restructuring charges and cost savings subject to certain limitations, and modified the definition of the consolidated interest coverage ratio to include, when calculating such ratio, consolidated interest expense “paid in cash” only.

Convertible Senior Notes

We have outstanding $550 million aggregate principal amount of 1.125% cash convertible senior notes due January 15, 2020 (1.125% Convertible Notes), unless earlier repurchased or converted. We also have outstanding $302 million aggregate principal amount of 1.625% convertible senior notes due August 14, 2044 (1.625% Convertible Notes), unless earlier repurchased, redeemed, or converted. The 1.125% Convertible Notes are convertible entirely into cash, and the 1.625% Convertible Notes are convertible partially into cash, each prior to their respective maturity dates under certain circumstances, one of which relates to the closing price of our common stock over a specified period. We refer to this conversion trigger as the stock price trigger.

The stock price trigger for the 1.125% Convertible Notes is $53.00 per share. The 1.125% Convertible Notes met this trigger in the quarter ended September 30, 2017; therefore, they are convertible into cash and are reported in current portion of long-term debt as of September 30, 2017.

The stock price trigger for the 1.625% Convertible Notes is $75.51 per share. The 1.625% Convertible Notes did not meet this stock price trigger in the quarter ended September 30, 2017. However, on contractually specified dates beginning in 2018, holders of the 1.625% Convertible Notes may require us to repurchase some or all of such notes. In addition, beginning May 15, 2018 until August 19, 2018, holders may convert some or all of the 1.625% Convertible Notes. Because of these put and conversion features, the 1.625% Convertible Notes are reported in current portion of long-term debt as of September 30, 2017. As noted above, because the proceeds from the 4.875% Notes are initially restricted to payments upon conversion or redemption of the 1.625% Convertible Notes, such restricted investments are also classified as current in the accompanying consolidated balance sheets.

Cross-Default Provisions

The terms of our 4.875% Notes, 5.375% Notes and each of the 1.125% and 1.625% Convertible Notes contain cross-default provisions with the Credit Facility that are triggered upon an event of default under the Credit Facility, and when borrowings under the Credit Facility equal or exceed certain amounts as defined in the related indentures.

Debt Commitment Letter

In connection with the terminated Medicare Acquisition, we entered into a debt commitment letter with Barclays Bank PLC (Barclays) in August 2016. Under this debt commitment letter, Barclays agreed to lend us up to $400 million, subject to satisfaction of certain conditions, including consummation of the terminated Medicare Acquisition. The debt commitment letter automatically terminated in February 2017 as a result of the termination of this transaction. The costs associated with the debt commitment letter and its termination were reimbursed as described in Note 1, “Basis of Presentation–Health Plans Segment Recent Developments.”

Derivatives

9 Months Ended

Sep. 30, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivatives

The following table summarizes the fair values and the presentation of our derivative financial instruments (defined and discussed individually below) in the accompanying consolidated balance sheets:



	Balance Sheet Location	September 30, 2017		December 31, 2016
		(In millions)
Derivative asset:
1.125% Call Option	Current assets: Derivative asset	$	425	$	267
Derivative liability:
1.125% Conversion Option	Current liabilities: Derivative liability	$	425	$	267

Our derivative financial instruments do not qualify for hedge treatment; therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of operations, and reported in “Other income, net.” Gains and losses for our derivative financial instruments are presented individually in the accompanying consolidated statements of cash flows, “Supplemental cash flow information.”

1.125% Notes Call Spread Overlay. Concurrent with the issuance of the 1.125% Convertible Notes in 2013, we entered into privately negotiated hedge transactions (collectively, the 1.125% Call Option) and warrant transactions (collectively, the 1.125% Warrants), with certain of the initial purchasers of the 1.125% Convertible Notes (the Counterparties). We refer to these transactions collectively as the Call Spread Overlay. Under the Call Spread Overlay, the cost of the 1.125% Call Option we purchased to cover the cash outlay upon conversion of the 1.125% Convertible Notes was reduced by proceeds from the sale of the 1.125% Warrants. Assuming full performance by the Counterparties (and 1.125% Warrants strike prices in excess of the conversion price of the 1.125% Convertible Notes), these transactions are intended to offset cash payments in excess of the principal amount of the 1.125% Convertible Notes due upon any conversion of such notes.

1.125% Call Option. The 1.125% Call Option, which is indexed to our common stock, is a derivative asset that requires mark-to-market accounting treatment due to cash settlement features until the 1.125% Call Option settles or expires. For further discussion of the inputs used to determine the fair value of the 1.125% Call Option, refer to Note 4, “Fair Value Measurements.”

1.125% Conversion Option. The embedded cash conversion option within the 1.125% Convertible Notes is accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations until the cash conversion option settles or expires. For further discussion of the inputs used to determine the fair value of the 1.125% Conversion Option, refer to Note 4, “Fair Value Measurements.”

As of September 30, 2017, the 1.125% Call Option and the 1.125% Conversion Option were classified as a current asset and current liability, respectively, because the 1.125% Convertible Notes may be converted within twelve months of September 30, 2017, as described in Note 7, “Debt.”

Stockholders' Equity

9 Months Ended

Sep. 30, 2017

Stockholders' Equity Note [Abstract]

Stockholders' Equity

Stockholders’ equity decreased $220 million during the nine months ended September 30, 2017 compared with stockholders’ equity at December 31, 2016. The decrease was due primarily to the net loss of $250 million, partially offset by $29 million related to employee stock transactions in the nine months ended September 30, 2017.

1.125% Warrants

In connection with the Call Spread Overlay transaction described in Note 8, “Derivatives,” in 2013, we issued 13,490,236 warrants with a strike price of $53.8475 per share. Under certain circumstances, beginning in April 2020, when the price of our common stock exceeds the strike price of the 1.125% Warrants, we will be obligated to issue shares of our common stock subject to a share delivery cap. The 1.125% Warrants could separately have a dilutive effect to the extent that the market value per share of our common stock exceeds the applicable strike price of the 1.125% Warrants. Refer to Note 3, “Net (Loss) Income per Share,” for dilution information for the periods presented. We will not receive any additional proceeds if the 1.125% Warrants are exercised.

Stock Incentive Plans

In connection with our equity incentive plans and employee stock purchase plan, approximately 702,000 shares of common stock vested or were purchased, net of shares used to settle employees’ income tax obligations, during the nine months ended September 30, 2017.

Except as noted below, we record share-based compensation as “General and administrative expenses” in the accompanying consolidated statements of operations. Restricted stock awards (RSAs), performance stock awards (PSAs) and performance stock units (PSUs) activity for the nine months ended September 30, 2017 is summarized below:



	Restricted Stock Awards		Performance Stock Awards		Performance Stock Units		Total		Weighted Average Grant Date Fair Value
Unvested balance, December 31, 2016	577,244		345,656		—		922,900		$	58.15
Granted	386,273		—		231,100		617,373		57.16
Vested	(391,680	)	(260,894	)	(139,272	)	(791,846	)	57.78
Forfeited	(69,346	)	—		—		(69,346	)	54.37
Unvested balance, September 30, 2017	502,491		84,762		91,828		679,081		57.61

The total fair value of RSAs granted during the nine months ended September 30, 2017 and 2016 was $19 million and $18 million, respectively. The total fair value of RSAs which vested during the nine months ended September 30, 2017 and 2016 was $21 million and $22 million, respectively.

No PSAs were granted during the nine months ended September 30, 2017. The total fair value of PSAs granted during the nine months ended September 30, 2016 was $15 million. The total fair value of PSAs which vested during the nine months ended September 30, 2017 was $15 million. No PSAs vested during the nine months ended September 30, 2016.

The total fair value of PSUs granted during the nine months ended September 30, 2017 was $16 million. The total fair value of PSUs which vested during the nine months ended September 30, 2017 was $9 million. There were no PSUs granted or vested in 2016.

During the nine months ended September 30, 2017, the vesting of 133,957 RSAs, 153,574 PSAs and 139,272 PSUs was accelerated in connection with the termination of our former Chief Executive Officer (CEO) and former Chief Financial Officer (CFO) in May 2017. Share-based compensation expense of $38 million was recorded during the nine months ended September 30, 2017, of which $23 million was recorded to “Restructuring and separation costs” in the accompanying consolidated statements of operations. See Note 11, “Restructuring and Separation Costs” for further discussion. We recorded share-based compensation expense of $24 million in the nine months ended September 30, 2016.

As of September 30, 2017, there was $27 million of total unrecognized compensation expense related to unvested RSAs, PSAs, and PSUs, which we expect to recognize over a remaining weighted-average period of 2.2 years and 1.9 years, respectively. This unrecognized compensation cost assumes an estimated forfeiture rate of 4.5% for non-executive employees as of September 30, 2017.

Impairment Losses

9 Months Ended

Sep. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Impairment Losses

Goodwill represents the excess of the purchase price over the fair value of net assets acquired in business combinations. Goodwill is not amortized, but is subject to an annual impairment test. We are required to test at least annually for impairment, or more frequently if adverse events or changes in circumstances indicate that the asset may be impaired. When testing goodwill for impairment, we may first assess qualitative factors, such as industry and market factors, cost factors, and changes in overall performance, to determine if it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. If our qualitative assessment indicates that goodwill impairment is more likely than not, we perform additional quantitative analysis. We may also elect to skip the qualitative testing and proceed directly to the quantitative testing.

An impairment loss is measured as the excess of the carrying amount of the reporting unit, including goodwill, over the fair value of the reporting unit. We estimate the fair values of our reporting units using discounted cash flows. We apply our weighted average cost of capital (WACC) as the best estimate to discount future estimated cash flows to present value. The WACC is based on externally available data considering market participants’ cost of equity and debt, and capital structure. In addition, we apply a terminal growth rate that corresponds to the reporting unit’s long-term growth prospects.

In the discounted cash flow analyses, we must make assumptions about a wide variety of internal and external factors, and consider the price that would be received to sell the reporting unit as a whole in an orderly transaction between market participants at the measurement date. Significant assumptions include financial projections of free cash flow (including significant assumptions about operations, capital requirements and income taxes), long-term growth rates for determining terminal value beyond the discretely forecasted periods, and discount rates.

Molina Medicaid Solutions Segment

As described in Note 11, “Restructuring and Separation Costs,” in the third quarter of 2017 we wrote off certain costs capitalized at our Molina Medicaid Solutions segment that supported our Health Plans segment provider information management processes to be re-designed. Although the intercompany revenues recorded by Molina Medicaid Solutions under this arrangement were insignificant on a consolidated basis, the termination of such revenue resulted in a triggering event for an interim goodwill impairment analysis of this segment in the third quarter of 2017. In the Molina Medicaid Solutions’ discounted cash flow model, we incorporated significant estimates and assumptions related to future periods, such as intercompany business support opportunities and prospects for new Medicaid management information systems contracts. Because management has determined that Molina Medicaid Solutions will provide fewer future benefits for its support of the Health Plans segment, the test resulted in a fair value less than Molina Medicaid Solutions’ carrying amount; therefore, we recorded a goodwill impairment loss for the difference, or $28 million, in the third quarter of 2017.

Other Segment

In the course of developing the Restructuring Plan in the second quarter of 2017, we determined that future benefits to be derived from our Pathways subsidiary, including the integration of its operations with our Health Plans segment, would be less than previously anticipated. In addition, poorer than expected year-to-date operating results, as well as lower projections of operating results for periods in the near term at our Pathways subsidiary, led us to conclude that a triggering event for an interim impairment analysis had occurred in the second quarter of 2017.

In the third quarter of 2017, management determined that Pathways will not provide future benefits relating to the integration of its operations with the Health Plans segment to the extent previously expected. Therefore, we conducted an additional interim impairment analysis.

Intangible assets. In the second quarter of 2017, we evaluated Pathways’ finite-lived intangible assets (customer relationships and contract licenses) for impairment, using undiscounted cash flows expected over the longest remaining useful life of the assets tested. Because the undiscounted cash flows over the remaining useful life were less than Pathways’ carrying amount, the intangible assets were impaired. We recorded an impairment loss for the carrying amount of the intangible assets, or $11 million, in the second quarter of 2017.

Goodwill. As noted above, we estimated Pathways’ fair value using discounted cash flows, incorporating significant estimates and assumptions related to future periods. Such estimates included anticipated client census which drives service revenue; the likelihood of future benefits to be derived from Pathways (including integration with our health plans); current prospects relating to the behavioral services labor market which drives cost of service revenue; and anticipated capital expenditures. The tests in each of the three months ended June 30, 2017, and September 30, 2017, resulted in a fair value less than Pathways’ carrying amount; therefore, we recorded an impairment loss for the difference. The Pathways goodwill impairment losses amounted to $101 million in the third quarter of 2017, and $59 million in the second quarter of 2017. In the second quarter of 2017, we also recorded a goodwill impairment loss of $2 million for a separate subsidiary in the Other segment that did not pass its impairment test.

There were no impairments of intangible assets or goodwill during 2016.

The goodwill impairment losses are recorded to the segments as indicated in following table, and reported as “Impairment losses” in the accompanying consolidated statements of operations.



	Health Plans			Molina Medicaid Solutions			Other			Total
	(In millions)
Historical goodwill	$	445		$	71		$	162		$	678
Accumulated impairment losses at December 31, 2016	(58		)	—			—			(58		)
Balance, December 31, 2016	387			71			162			620
Impairment losses, three months ended June 30, 2017	—			—			(61		)	(61		)
Impairment losses, three months ended September 30, 2017	—			(28		)	(101		)	(129		)
Balance, September 30, 2017	$	387		$	43		$	—		$	430
Accumulated impairment losses at September 30, 2017	$	58		$	28		$	162		$	248

Restructuring and Separation Costs

9 Months Ended

Sep. 30, 2017

Restructuring and Related Activities [Abstract]

Restructuring and Separation Costs

Following a management-initiated, broad operational assessment in early 2017, designed to improve our profitability and expand our core Medicaid business, in June 2017, we accelerated the implementation of a comprehensive restructuring and profitability improvement plan (the Restructuring Plan). Under the Restructuring Plan, we are taking the following actions:


1.	We have streamlined our organizational structure, including the elimination of redundant layers of management, the consolidation of regional support services, and other reductions to our workforce, to improve efficiency as well as the speed and quality of our decision-making.


2.	We are re-designing core operating processes such as provider payment, utilization management, quality monitoring and improvement, and information technology to achieve more effective and cost efficient outcomes.


3.	We are remediating high cost provider contracts and building around high quality, cost-effective networks.


4.	We are restructuring our existing direct delivery operations.


5.	We are reviewing our vendor base to ensure that we are partnering with the lowest-cost, most-effective vendors.


6.	Throughout this process, we are taking precautions to ensure that our actions do not impede our ability to continue to deliver quality health care, retain existing managed care contracts, and to secure new managed care contracts.

In addition to costs incurred under the Restructuring Plan, we have recorded costs associated with the separation of our former CEO and former CFO, described in further detail below.

Expected Costs

We estimate that total pre-tax costs associated with the restructuring plan will be approximately $70 million to $90 million in the fourth quarter of 2017, with an additional $20 million to $40 million to be incurred in 2018. Since the initiation of our Restructuring Plan in the second quarter of 2017, the range of total estimated costs have increased by approximately $50 million due primarily to non-cash write-offs of certain capitalized software in connection with the re-design of core processes. Such write-offs were not included in our initial total cost estimates, but as our evaluation of core operating processes proceeded in the third quarter, we determined that certain projects were inconsistent with our future operating goals and were therefore written off.

In addition, in the second quarter of 2017, we reported that we expected restructuring costs to relate only to the Health Plans and Other segments. In the third quarter of 2017, however, we wrote off certain costs capitalized at our Molina Medicaid Solutions segment that supported our Health Plans segment provider information management processes to be re-designed. In addition, we now expect to incur consulting fees in connection with the review of Molina Medicaid Solutions’ core operating processes.

The following table illustrates our estimates of the total costs, by segment and major type of cost, that we expect to incur under the Restructuring Plan, and includes costs incurred through September 30, 2017. We expect the Restructuring Plan to be completed by the end of 2018.



Estimated Costs Expected to be Incurred by Reportable Segment	Health Plans	Molina Medicaid Solutions	Other	Total
	(In millions)
Termination benefits	$30 to $35	—	$30 to $35	$60 to $70
Other restructuring costs	$40 to $45	$10	$110 to $115	$160 to $170
	$70 to $80	$10	$140 to $150	$220 to $240

Costs Incurred

Restructuring Plan

Restructuring costs incurred to date consist primarily of termination benefits, write-offs of capitalized software due to the re-design of our core operating processes, restructuring of our direct delivery operations, and consulting fees.

Separation Costs

On May 2, 2017, we terminated the employment of our former CEO and CFO without cause. Under their amended and restated employment agreements, they were each entitled to receive 400% of their base salary, a prorated termination bonus (150% of base salary for the former CEO and 125% of base salary for the former CFO), full vesting of equity compensation, and a cash payment for health and welfare benefits. We recorded separation costs of $35 million primarily related to these former executives under FASB ASC Topic 712, Nonretirement and Postemployment Benefits. Of this total, $23 million related to the acceleration of their share-based compensation, as further discussed in Note 9, “Stockholders' Equity.” Employee separation costs were insignificant in 2016.

Restructuring and separation costs are reported in “Restructuring and separation costs” in the accompanying consolidated statements of operations. The following tables present the major types of such costs by segment. Long-lived assets include capitalized software, intangible assets and furniture, fixtures and equipment.



	Three Months Ended September 30, 2017
	Separation Costs - Former Executives		One-Time Termination Benefits		Other Restructuring Costs						Total
	Separation Costs - Former Executives		One-Time Termination Benefits		Write-offs of Long-lived Assets		Consulting Fees		Contract Termination Costs		Total
	(In millions)
Health Plans	$	—	$	27	$	6	$	—	$	—	$	33
Molina Medicaid Solutions	—		—		8		—		—		8
Other	—		23		35		16		3		77
	$	—	$	50	$	49	$	16	$	3	$	118



	Nine Months Ended September 30, 2017
	Separation Costs - Former Executives		One-Time Termination Benefits		Other Restructuring Costs						Total
	Separation Costs - Former Executives		One-Time Termination Benefits		Write-offs of Long-lived Assets		Consulting Fees		Contract Termination Costs		Total
	(In millions)
Health Plans	$	—	$	27	$	6	$	—	$	—	$	33
Molina Medicaid Solutions	—		—		8		—		—		8
Other	35		23		35		24		3		120
	$	35	$	50	$	49	$	24	$	3	$	161

Reconciliation of Liability

For those restructuring and separation costs that require cash settlement (primarily separation costs, termination benefits and consulting fees), the following table presents a roll-forward of the accrued liability, which is reported in “Accounts payable and accrued liabilities” in the accompanying consolidated balance sheets:



	Separation Costs - Former Executives			One-Time Termination Benefits			Other Restructuring Costs			Total
	(In millions)
Accrued as of December 31, 2016	$	—		$	—		$	—		$	—
Charges	12			50			27			89
Cash payments	(1		)	(9		)	(14		)	(24		)
Accrued as of September 30, 2017	$	11		$	41		$	13		$	65

Segment Information

9 Months Ended

Sep. 30, 2017

Segment Reporting [Abstract]

Segment Information

We have three reportable segments. These segments consist of our Health Plans segment, which constitutes the vast majority of our operations; our Molina Medicaid Solutions segment; and our Other segment. Our reportable segments are consistent with how we currently manage the business and view the markets we serve.

Gross margin is the appropriate earnings measure for our reportable segments, based on how our chief operating decision maker currently reviews results, assesses performance, and allocates resources.

Gross margin for our Health Plans segment is referred to as “Medical margin,” and for our Molina Medicaid Solutions and Other segments, as “Service margin.” Medical margin represents the amount earned by the Health Plans segment after medical costs are deducted from premium revenue. The medical care ratio represents medical care costs as a percentage of premium revenue, and is one of the key metrics used to assess the performance of the Health Plans segment. Therefore, the underlying medical margin is the most important measure of earnings reviewed by the chief operating decision maker. The service margin is equal to service revenue minus cost of service revenue.



	Health Plans			Molina Medicaid Solutions			Other			Consolidated
	Health Plans			Molina Medicaid Solutions			Other			Consolidated
	(In millions)
Three Months Ended September 30, 2017
Total revenue ⁽¹⁾	$	4,899		$	47		$	85		$	5,031
Gross margin	557			5			2			564
Impairment losses	—			(28		)	(101		)	(129		)
Restructuring and separation costs	(33		)	(8		)	(77		)	(118		)

Nine Months Ended September 30, 2017
Total revenue ⁽¹⁾	$	14,538		$	140		$	256		$	14,934
Gross margin	1,343			13			8			1,364
Impairment losses	—			(28		)	(173		)	(201		)
Restructuring and separation costs	(33		)	(8		)	(120		)	(161		)

Three Months Ended September 30, 2016
Total revenue ⁽¹⁾	$	4,412		$	48		$	86		$	4,546
Gross margin	443			6			8			457
Impairment losses	—			—			—			—
Restructuring and separation costs	—			—			—			—

Nine Months Ended September 30, 2016
Total revenue ⁽¹⁾	$	12,835		$	146		$	267		$	13,248
Gross margin	1,285			17			29			1,331
Impairment losses	—			—			—			—
Restructuring and separation costs	—			—			—			—

Total assets
September 30, 2017	$	7,031		$	233		$	1,690		$	8,954
December 31, 2016	5,897			267			1,285			7,449

Goodwill and intangible assets, net
September 30, 2017	$	488		$	43		$	—		$	531
December 31, 2016	513			72			175			760

______________________


(1)	Total revenue consists primarily of premium revenue, premium tax revenue and health insurer fee revenue for the Health Plans segment, and service revenue for the Molina Medicaid Solutions and Other segments. Inter-segment revenue is insignificant for all periods presented.

The following table reconciles gross margin by segment to consolidated income before income tax expense:



	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
	(In millions)
Gross margin:
Health Plans	$	557		$	443		$	1,343		$	1,285
Molina Medicaid Solutions	5			6			13			17
Other	2			8			8			29
Total gross margin	564			457			1,364			1,331
Add: other operating revenues ⁽¹⁾	124			222			379			625
Less: other operating expenses ⁽²⁾	(769		)	(561		)	(2,029		)	(1,644		)
Operating (loss) income	(81		)	118			(286		)	312
Other expenses, net	32			26			10			76
(Loss) income before income taxes	$	(113	)	$	92		$	(296	)	$	236

______________________


(1)	Other operating revenues include premium tax revenue, health insurer fee revenue, investment income and other revenue.


(2)	Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fee expenses, depreciation and amortization, impairment losses, and restructuring and separation costs.

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Regulatory Capital Requirements and Dividend Restrictions Our health plans, which are operated by our wholly owned subsidiaries in the states in which our health plans operate, are subject to state laws and regulations that, among other things, require the maintenance of minimum levels of statutory capital, as defined by each state. Regulators in some states may also attempt to enforce capital requirements that require the retention of net worth in excess of amounts formally required by statute or regulation. Such statutes, regulations and informal capital requirements also restrict the timing, payment, and amount of dividends and other distributions that may be paid to us as the sole stockholder. To the extent our subsidiaries must comply with these regulations, they may not have the financial flexibility to transfer funds to us. Based on current statutes and regulations, the net assets in these subsidiaries (after intercompany eliminations) which may not be transferable to us in the form of loans, advances, or cash dividends was approximately $1,696 million at September 30, 2017, and $1,492 million at December 31, 2016. Because of the statutory restrictions that inhibit the ability of our health plans to transfer net assets to us, the amount of retained earnings readily available to pay dividends to our stockholders is generally limited to cash, cash equivalents and investments (excluding restricted investments) held by the parent company – Molina Healthcare, Inc. Such cash, cash equivalents and investments (excluding restricted investments) amounted to $391 million and $264 million as of September 30, 2017 and December 31, 2016, respectively. The National Association of Insurance Commissioners (NAIC) adopted rules effective December 31, 1998, which, if implemented by the states, set minimum capitalization requirements for insurance companies, HMOs, and other entities bearing risk for health care coverage. The requirements take the form of risk-based capital (RBC) rules which may vary from state to state. All of the states in which our health plans operate, except California, Florida and New York, have adopted these rules. Such requirements, if adopted by California, Florida and New York, may increase the minimum capital required for those states. As of September 30, 2017, our health plans had aggregate statutory capital and surplus of approximately $1,828 million compared with the required minimum aggregate statutory capital and surplus of approximately $1,113 million. All of our health plans were in compliance with the minimum capital requirements at September 30, 2017. We have the ability, and have committed to provide, additional capital to each of our health plans as necessary to ensure compliance with statutory capital and surplus requirements. Legal Proceedings The health care and Medicaid-related business process outsourcing industries are subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. Penalties associated with violations of these laws and regulations include significant fines, exclusion from participating in publicly funded programs, and the repayment of previously billed and collected revenues. We are involved in legal actions in the ordinary course of business, some of which seek monetary damages, including claims for punitive damages, which are not covered by insurance. We have accrued liabilities for certain matters for which we deem the loss to be both probable and reasonably estimable, but the outcome of legal actions is inherently uncertain and our estimates of such losses could change as a result of further developments of these matters. For certain pending matters, accruals have not been established because such matters have not progressed sufficiently through discovery, and/or development of important factual information and legal issues is insufficient to enable us to estimate a range of possible loss, if any. An adverse determination in one or more of these pending matters could have a material adverse effect on our consolidated financial position, results of operations, or cash flows. Marketplace Risk Corridor Program. On January 19, 2017, we filed suit against the United States of America in the United States Court of Federal Claims, Case Number 1:55-cv-01000-UNJ, on behalf of our health plans seeking recovery from the federal government of approximately $52 million in Marketplace risk corridor payments for calendar year 2015. Based upon current estimates, we believe our health plans are also owed approximately $76 million in Marketplace risk corridor payments from the federal government for calendar year 2016. We have not recognized revenue, nor have we recorded a receivable, for any amount due from the federal government for unpaid Marketplace risk corridor payments as of September 30, 2017. We have fully recognized all liabilities due to the federal government that we have incurred under the Marketplace risk corridor program, and have paid all amounts due to the federal government as required. Rodriguez v. Providence Community Corrections. On October 1, 2015, seven individuals, on behalf of themselves and all others similarly situated, filed a complaint in the District Court for the Middle District of Tennessee, Nashville Division, Case No. 3:15-cv-01048 (the Rodriquez Litigation), against Providence Community Corrections, Inc. (now known as Pathways Community Corrections, Inc., or PCC). Rutherford County, Tennessee formerly contracted with PCC for the administration of misdemeanor probation, which involved the collection of court costs and fees from probationers. The complaint alleges, among other things, that PCC illegally assessed fees and surcharges against probationers and made improper threats of arrest and probation revocation if the probationers did not pay such amounts. The plaintiffs in the Rodriguez Litigation seek alleged compensatory, treble, and punitive damages, plus attorneys’ fees, for alleged federal and state constitutional violations, as well as alleged violations of the Racketeer Influenced and Corrupt Organization Act. PCC’s agreement with Rutherford County terminated effective March 31, 2016. On November 1, 2015, one month after the Rodriguez Litigation commenced, we acquired PCC from The Providence Service Corporation (Providence) pursuant to a membership interest purchase agreement. In September 2016, the parties to the Rodriguez Litigation accepted a mediation proposal for settlement pursuant to which PCC and Rutherford County would pay the plaintiffs $14 million and $3 million, respectively. The parties are in the process of finalizing the settlement agreement. We expect to recover the full amount of the settlement under the indemnification provisions of the membership interest purchase agreement with Providence. United States of America, ex rel., Anita Silingo v. Mobile Medical Examination Services, Inc., et al. On or around October 14, 2014, Molina Healthcare of California, Molina Healthcare of California Partner Plan, Inc., Mobile Medical Examination Services, Inc. (MedXM), and other health plan defendants were served with a complaint previously filed under seal in the Central District Court of California by Relator, Anita Silingo, Case No. SACV13-1348-FMO(SHx). The complaint alleges that MedXM improperly modified medical records and otherwise took inappropriate steps to increase members’ risk adjustment scores, and that the defendants, including Molina Healthcare of California and Molina Healthcare of California Partner Plan, Inc., purportedly turned a “blind eye” to these unlawful practices. On October 22, 2015, the Relator filed a third amended complaint, seeking general and compensatory damages, treble damages, civil penalties, plus interest and attorneys’ fees. On July 11, 2016, the District Court dismissed with prejudice the third amended complaint, without leave to amend. On September 23, 2016, the plaintiff filed an appeal with the Ninth Circuit Court of Appeals. The appeal has been fully briefed by the parties and we are awaiting the Court’s decision. States’ Budgets From time to time, the states in which our health plans operate may experience financial difficulties, which could lead to delays in premium payments. Until July 4, 2017, the state of Illinois operated without a budget for its current fiscal year. As of September 30, 2017, our Illinois health plan served approximately 163,000 members, and recognized premium revenue of approximately $447 million in the nine months ended September 30, 2017. As of September 30, 2017, the state of Illinois owed us approximately $220 million for certain March through September 2017 premiums. On May 3, 2017, Puerto Rico’s financial oversight board filed for a form of bankruptcy in the U.S. District Court in Puerto Rico under Title III of PROMESA. The Title III provision allows for a court debt restructuring process similar to U.S. bankruptcy protection. To the extent such bankruptcy results in our failure to receive payment of amounts due under our Medicaid contract with the Commonwealth or the inability of the Commonwealth to extend our Medicaid contract at the end of its current term, such bankruptcy could have a material adverse effect on our business, financial condition, cash flows, or results of operations. As of September 30, 2017, the plan served approximately 306,000 members and recorded premium revenue of approximately $553 million in the nine months ended September 30, 2017. As of October 27, 2017, the Commonwealth was current with its premium payments.

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Our California health plan has entered into a provider agreement with Pacific Healthcare IPA (Pacific), which is 50% owned by the brother-in-law of Dr. J. Mario Molina and John C. Molina, who are members of our board of directors. Under the terms of this provider agreement, the California health plan pays Pacific for medical care Pacific provides to health plan members. For the three and nine months ended September 30, 2017 and 2016, the amounts paid to Pacific were insignificant. Refer to Note 15, “Variable Interest Entities (VIEs),” for a discussion of the Joseph M. Molina, M.D. Professional Corporations.

Variable Interest Entities (VIEs)	9 Months Ended
Variable Interest Entities (VIEs)	Sep. 30, 2017
Variable Interest Entities [Abstract]
Variable Interest Entities (VIEs)	Variable Interest Entities (VIEs) The Joseph M. Molina, M.D. Professional Corporations (JMMPC) were created to further advance our direct delivery business. Effective September 30, 2017, we terminated our relationship with JMMPC in Florida, Michigan, Washington, and Utah. Therefore, the agreements described below, for all of our health plans other than those in California and New Mexico, were terminated effective September 30, 2017. JMMPC’s primary shareholder is Dr. J. Mario Molina, who is a member of our board of directors. Dr. Molina is paid no salary and receives no dividends in connection with his work for, or ownership of, JMMPC. JMMPC provides primary care medical services through its employed physicians and other medical professionals. JMMPC also provides certain specialty referral services to our California health plan members through a contracted provider network. The health plans had entered into primary care services agreements with JMMPC, under which the health plans paid $29 million and $31 million to JMMPC for health care services provided in the three months ended September 30, 2017 and 2016, respectively, and $89 million and $92 million for the nine months ended September 30, 2017 and 2016, respectively. JMMPC does not have agreements to provide professional medical services with any other entities. Our wholly owned subsidiary, Molina Medical Management, Inc. (MMM), had also entered into services agreements with JMMPC to provide clinic facilities, clinic administrative support staff, patient scheduling services and medical supplies to JMMPC. For the three months ended September 30, 2017 and 2016, JMMPC paid $12 million and $13 million to MMM for clinic administrative services, respectively. For the nine months ended September 30, 2017 and 2016, JMMPC paid $38 million and $40 million, respectively, to MMM for clinic administrative services. As of September 30, 2017, we determined that JMMPC is a VIE, and that we are its primary beneficiary. We reached this conclusion under the power and benefits criterion model according to GAAP. Specifically, we had the power to direct the activities (excluding clinical decisions) that most significantly affected JMMPC’s economic performance, and the obligation to absorb losses or right to receive benefits that were potentially significant to the VIE, under the agreements described above. Because we were its primary beneficiary, we consolidated JMMPC. JMMPC’s assets may be used to settle only JMMPC’s obligations, and JMMPC’s creditors have no recourse to the general credit of Molina Healthcare, Inc. As of September 30, 2017, JMMPC had total assets of $20 million, and total liabilities of $24 million. As of December 31, 2016, JMMPC had total assets of $18 million, and total liabilities of $18 million. Our maximum exposure to loss as a result of our involvement with JMMPC is generally limited to the amounts needed to fund JMMPC’s ongoing payroll, employee benefits and medical care costs associated with JMMPC’s specialty referral activities.

Supplemental Condensed Consolidating Financial Information

9 Months Ended

Sep. 30, 2017

Condensed Financial Information [Abstract]

Supplemental Condensed Consolidating Financial Information

The 5.375% Notes described in Note 7, “Debt,” are fully and unconditionally guaranteed by certain of our 100% owned subsidiaries on a joint and several basis, with certain exceptions considered customary for such guarantees. The 5.375% Notes and the guarantees are effectively subordinated to all of our and our guarantors’ existing and future secured debt to the extent of the assets securing such debt. In addition, the 5.375% Notes and the guarantees are structurally subordinated to all indebtedness and other liabilities and preferred stock, if any, of our subsidiaries that do not guarantee the 5.375% Notes.

As discussed in Note 7, “Debt,” the First Amendment to the Credit Facility provided that all guarantors immediately prior to January 3, 2017, other than Molina Information Systems, LLC, d/b/a Molina Medicaid Solutions, Molina Pathways, LLC, and Pathways Health and Community Support LLC, were automatically and unconditionally released from their obligations as guarantors under the Credit Facility and the 5.375% Notes.

The following condensed consolidating financial statements present Molina Healthcare, Inc. (as parent guarantor), the subsidiary guarantors, the subsidiary non-guarantors and eliminations, according to the guarantor structure as assessed at the most recent balance sheet date, September 30, 2017.

CONDENSED CONSOLIDATING STATEMENTS OF OPERATIONS



	Three Months Ended September 30, 2017
	Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations			Consolidated
	(In millions)
Revenue:
Total revenue	$	380		$	47		$	4,983		$	(379	)	$	5,031
Expenses:
Medical care costs	3			—			4,217			—			4,220
Cost of service revenue	—			42			81			—			123
General and administrative expenses	244			(1		)	519			(379		)	383
Premium tax expenses	—			—			106			—			106
Depreciation and amortization	23			1			9			—			33
Impairment losses	—			28			101			—			129
Restructuring and separation costs	77			8			33			—			118
Total operating expenses	347			78			5,066			(379		)	5,112
Operating income (loss)	33			(31		)	(83		)	—			(81		)
Interest expense	32			—			—			—			32
Income (loss) before income taxes	1			(31		)	(83		)	—			(113		)
Income tax expense (benefit)	9			(10		)	(15		)	—			(16		)
Net loss before equity in net losses of subsidiaries	(8		)	(21		)	(68		)	—			(97		)
Equity in net losses of subsidiaries	(89		)	(77		)	—			166			—
Net loss	$	(97	)	$	(98	)	$	(68	)	$	166		$	(97	)

CONDENSED CONSOLIDATING STATEMENTS OF COMPREHENSIVE LOSS



	Three Months Ended September 30, 2017
	Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations		Consolidated
	(In millions)
Net loss	$	(97	)	$	(98	)	$	(68	)	$	166	$	(97	)
Other comprehensive loss, net of tax	—			—			—			—		—
Comprehensive loss	$	(97	)	$	(98	)	$	(68	)	$	166	$	(97	)

CONDENSED CONSOLIDATING STATEMENTS OF INCOME



	Three Months Ended September 30, 2016
	Parent Guarantor			Other Guarantors			Non-Guarantors		Eliminations			Consolidated
	(In millions)
Revenue:
Total revenue	$	274		$	48		$	4,498	$	(274	)	$	4,546
Expenses:
Medical care costs	19			—			3,730		(1		)	3,748
Cost of service revenue	—			42			77		—			119
General and administrative expenses	223			(4		)	397		(273		)	343
Premium tax expenses	—			—			127		—			127
Health insurer fee expenses	—			—			55		—			55
Depreciation and amortization	25			2			9		—			36
Total operating expenses	267			40			4,395		(274		)	4,428
Operating income	7			8			103		—			118
Interest expense	26			—			—		—			26
(Loss) income before income taxes	(19		)	8			103		—			92
Income tax expense	4			—			46		—			50
Net (loss) income before equity in net earnings of subsidiaries	(23		)	8			57		—			42
Equity in net earnings of subsidiaries	65			—			—		(65		)	—
Net income	$	42		$	8		$	57	$	(65	)	$	42

CONDENSED CONSOLIDATING STATEMENTS OF COMPREHENSIVE INCOME



	Three Months Ended September 30, 2016
	Parent Guarantor			Other Guarantors		Non-Guarantors			Eliminations			Consolidated

	(In millions)
Net income	$	42		$	8	$	57		$	(65	)	$	42
Other comprehensive loss, net of tax	(1		)	—		(1		)	1			(1		)
Comprehensive income	$	41		$	8	$	56		$	(64	)	$	41

CONDENSED CONSOLIDATING STATEMENTS OF OPERATIONS



	Nine Months Ended September 30, 2017
	Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations			Consolidated
	(In millions)
Revenue:
Total revenue	$	1,010		$	146		$	14,792		$	(1,014	)	$	14,934
Expenses:
Medical care costs	10			—			12,812			—			12,822
Cost of service revenue	—			127			242			—			369
General and administrative expenses	799			13			1,429			(1,014		)	1,227
Premium tax expenses	—			—			331			—			331
Depreciation and amortization	75			1			33			—			109
Impairment losses	—			28			173			—			201
Restructuring and separation costs	120			8			33			—			161
Total operating expenses	1,004			177			15,053			(1,014		)	15,220
Operating income (loss)	6			(31		)	(261		)	—			(286		)
Interest expense	85			—			—			—			85
Other income, net	(75		)	—			—			—			(75		)
Loss before income taxes	(4		)	(31		)	(261		)	—			(296		)
Income tax expense (benefit)	26			(10		)	(62		)	—			(46		)
Net loss before equity in net losses of subsidiaries	(30		)	(21		)	(199		)	—			(250		)
Equity in net losses of subsidiaries	(220		)	(143		)	—			363			—
Net loss	$	(250	)	$	(164	)	$	(199	)	$	363		$	(250	)

CONDENSED CONSOLIDATING STATEMENTS OF COMPREHENSIVE LOSS



	Nine Months Ended September 30, 2017
	Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations			Consolidated
	(In millions)
Net loss	$	(250	)	$	(164	)	$	(199	)	$	363		$	(250	)
Other comprehensive income, net of tax	1			—			1			(1		)	1
Comprehensive loss	$	(249	)	$	(164	)	$	(198	)	$	362		$	(249	)

CONDENSED CONSOLIDATING STATEMENTS OF INCOME



	Nine Months Ended September 30, 2016
	Parent Guarantor			Other Guarantors			Non-Guarantors		Eliminations			Consolidated
	(In millions)
Revenue:
Total revenue	$	786		$	147		$	13,099	$	(784	)	$	13,248
Expenses:
Medical care costs	50			—			10,881		(1		)	10,930
Cost of service revenue	—			130			232		—			362
General and administrative expenses	659			5			1,153		(783		)	1,034
Premium tax expenses	—			—			345		—			345
Health insurer fee expenses	—			—			163		—			163
Depreciation and amortization	70			5			27		—			102
Total operating expenses	779			140			12,801		(784		)	12,936
Operating income	7			7			298		—			312
Interest expense	76			—			—		—			76
(Loss) income before income taxes	(69		)	7			298		—			236
Income tax (benefit) expense	(24		)	(1		)	162		—			137
Net (loss) income before equity in earnings of subsidiaries	(45		)	8			136		—			99
Equity in net earnings of subsidiaries	144			3			—		(147		)	—
Net income	$	99		$	11		$	136	$	(147	)	$	99

CONDENSED CONSOLIDATING STATEMENTS OF COMPREHENSIVE INCOME



	Nine Months Ended September 30, 2016
	Parent Guarantor		Other Guarantors		Non-Guarantors		Eliminations			Consolidated
	(In millions)
Net income	$	99	$	11	$	136	$	(147	)	$	99
Other comprehensive income, net of tax	7		—		6		(6		)	7
Comprehensive income	$	106	$	11	$	142	$	(153	)	$	106

CONDENSED CONSOLIDATING BALANCE SHEETS



	September 30, 2017
	Parent Guarantor		Other Guarantors			Non-Guarantors			Eliminations			Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	356	$	58		$	3,520		$	—		$	3,934
Investments	35		—			1,752			—			1,787
Restricted investments	326		—			—			—			326
Receivables	2		25			975			—			1,002
Income taxes refundable	2		—			58			—			60
Due from (to) affiliates	203		(5		)	(198		)	—			—
Prepaid expenses and other current assets	65		20			89			—			174
Derivative asset	425		—			—			—			425
Total current assets	1,414		98			6,196			—			7,708
Property, equipment, and capitalized software, net	261		37			99			—			397
Deferred contract costs	—		97			—			—			97
Goodwill and intangible assets, net	55		43			433			—			531
Restricted investments	—		—			117			—			117
Investment in subsidiaries, net	2,625		95			—			(2,720		)	—
Deferred income taxes	10		—			96			(44		)	62
Other assets	50		2			6			(16		)	42
	$	4,415	$	372		$	6,947		$	(2,780	)	$	8,954

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Medical claims and benefits payable	$	—	$	—		$	2,478		$	—		$	2,478
Amounts due government agencies	—		—			1,324			—			1,324
Accounts payable and accrued liabilities	227		40			218			—			485
Deferred revenue	—		52			416			—			468
Current portion of long-term debt	782		—			—			—			782
Derivative liability	425		—			—			—			425
Total current liabilities	1,434		92			4,436			—			5,962
Long-term debt	1,515		—			16			(16		)	1,515
Deferred income taxes	12		32			—			(44		)	—
Other long-term liabilities	25		1			22			—			48
Total liabilities	2,986		125			4,474			(60		)	7,525
Total stockholders’ equity	1,429		247			2,473			(2,720		)	1,429
	$	4,415	$	372		$	6,947		$	(2,780	)	$	8,954

CONDENSED CONSOLIDATING BALANCE SHEETS



	December 31, 2016
	Parent Guarantor		Other Guarantors			Non-Guarantors			Eliminations			Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	86	$	6		$	2,727		$	—		$	2,819
Investments	178		—			1,580			—			1,758
Receivables	2		34			938			—			974
Income tax refundable	17		4			18			—			39
Due from (to) affiliates	104		(5		)	(99		)	—			—
Prepaid expenses and other current assets	58		30			43			—			131
Derivative asset	267		—			—			—			267
Total current assets	712		69			5,207			—			5,988
Property, equipment, and capitalized software, net	301		46			107			—			454
Deferred contract costs	—		86			—			—			86
Goodwill and intangible assets, net	58		73			629			—			760
Restricted investments	—		—			110			—			110
Investment in subsidiaries, net	2,609		246			—			(2,855		)	—
Deferred income taxes	10		—			—			—			10
Other assets	48		3			6			(16		)	41
	$	3,738	$	523		$	6,059		$	(2,871	)	$	7,449

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Medical claims and benefits payable	$	1	$	—		$	1,928		$	—		$	1,929
Amounts due government agencies	—		—			1,202			—			1,202
Accounts payable and accrued liabilities	146		34			205			—			385
Deferred revenue	—		40			275			—			315
Current portion of long-term debt	472		—			—			—			472
Derivative liability	267		—			—			—			267
Total current liabilities	886		74			3,610			—			4,570
Long-term debt	1,173		—			16			(16		)	1,173
Deferred income taxes	11		39			(35		)	—			15
Other long-term liabilities	19		1			22			—			42
Total liabilities	2,089		114			3,613			(16		)	5,800
Total stockholders’ equity	1,649		409			2,446			(2,855		)	1,649
	$	3,738	$	523		$	6,059		$	(2,871	)	$	7,449

CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS



	Nine Months Ended September 30, 2017
	Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations		Consolidated
	(In millions)
Operating activities:
Net cash provided by operating activities	$	215		$	81		$	661		$	—	$	957
Investing activities:
Purchases of investments	(333		)	—			(1,563		)	—		(1,896		)
Proceeds from sales and maturities of investments	150			—			1,388			—		1,538
Purchases of property, equipment and capitalized software	(67		)	(10		)	(8		)	—		(85		)
Increase in restricted investments held-to-maturity	—			—			(10		)	—		(10		)
Capital contributions to/from subsidiaries	(363		)	2			361			—		—
Dividends to/from subsidiaries	136			—			(136		)	—		—
Change in amounts due to/from affiliates	(100		)	—			100			—		—
Other, net	—			(21		)	—			—		(21		)
Net cash (used in) provided by investing activities	(577		)	(29		)	132			—		(474		)
Financing activities:
Proceeds from senior notes offering, net of issuance costs	325			—			—			—		325
Proceeds from borrowings under credit facility	300			—			—			—		300
Proceeds from employee stock plans	11			—			—			—		11
Other, net	(4		)	—			—			—		(4		)
Net cash provided by financing activities	632			—			—			—		632
Net increase in cash and cash equivalents	270			52			793			—		1,115
Cash and cash equivalents at beginning of period	86			6			2,727			—		2,819
Cash and cash equivalents at end of period	$	356		$	58		$	3,520		$	—	$	3,934

CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS



	Nine Months Ended September 30, 2016
	Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations		Consolidated
	(In millions)
Operating activities:
Net cash provided by operating activities	$	43		$	34		$	556		$	—	$	633
Investing activities:
Purchases of investments	(114		)	—			(1,330		)	—		(1,444		)
Proceeds from sales and maturities of investments	103			—			1,409			—		1,512
Purchases of property, equipment and capitalized software	(102		)	(23		)	(18		)	—		(143		)
Decrease in restricted investments held-to-maturity	—			—			4			—		4
Net cash paid in business combinations	—			(5		)	(43		)	—		(48		)
Capital contributions to/from subsidiaries	(221		)	7			214			—		—
Dividends to/from subsidiaries	50			—			(50		)	—		—
Change in amounts due to/from affiliates	(12		)	4			8			—		—
Other, net	6			(19		)	1			—		(12		)
Net cash (used in) provided by investing activities	(290		)	(36		)	195			—		(131		)
Financing activities:
Proceeds from employee stock plans	10			—			—			—		10
Other, net	2			—			(1		)	—		1
Net cash provided by (used in) financing activities	12			—			(1		)	—		11
Net (decrease) increase in cash and cash equivalents	(235		)	(2		)	750			—		513
Cash and cash equivalents at beginning of period	360			13			1,956			—		2,329
Cash and cash equivalents at end of period	$	125		$	11		$	2,706		$	—	$	2,842

Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Consolidation and Interim Financial Information

The consolidated financial statements include the accounts of Molina Healthcare, Inc., its subsidiaries, and variable interest entities (VIEs) in which Molina Healthcare, Inc. is considered to be the primary beneficiary. Such VIEs are insignificant to our consolidated financial position and results of operations. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the current interim period are not necessarily indicative of the results for the entire year ending December 31, 2017.

The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December 31, 2016. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in the December 31, 2016 audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our December 31, 2016 audited consolidated financial statements.

Revenue Recognition – Health Plans Segment

Contractual Provisions That May Adjust or Limit Revenue or Profit

Medicaid

Medicare

Marketplace



	September 30, 2017								December 31, 2016
	Current Benefit Year			Prior Benefit Years		Total			December 31, 2016

	(In millions)
Risk adjustment	$	(655	)	$	—	$	(655	)	$	(522	)
Reinsurance	—			10		10			55
Risk corridor	—			—		—			(1		)
Minimum MLR	(27		)	—		(27		)	(1		)

•


•	Reinsurance: This program was designed to provide reimbursement to insurers for high cost members and ended December 31, 2016; we expect to settle the outstanding receivable balance in 2017.


•	Risk corridor: This program was intended to limit gains and losses of insurers by comparing allowable costs to a target amount as defined by CMS, and ended December 31, 2016; all outstanding balances were settled as of September 30, 2017.

Quality Incentives

At several of our health plans, revenue ranging from approximately 1% to 3% of certain health plan premiums is earned only if certain performance measures are met.

Income Taxes

Premium Deficiency Reserves on Loss Contracts

Recent Accounting Pronouncements

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Receivables (payables) for 3R programs

Our receivables (payables) for each of these programs, as of the dates indicated, were as follows:



	September 30, 2017								December 31, 2016
	Current Benefit Year			Prior Benefit Years		Total			December 31, 2016

	(In millions)
Risk adjustment	$	(655	)	$	—	$	(655	)	$	(522	)
Reinsurance	—			10		10			55
Risk corridor	—			—		—			(1		)
Minimum MLR	(27		)	—		(27		)	(1		)

Quality incentive premium revenue recognized



	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
	(Dollars in millions)
Maximum available quality incentive premium - current period	$	36		$	33		$	113		$	114
Quality incentive premium revenue recognized in current period:
Earned current period	$	24		$	26		$	72		$	80
Earned prior periods	3			—			9			54
Total	$	27		$	26		$	81		134

Quality incentive premium revenue recognized as a percentage of total premium revenue	0.6		%	0.6		%	0.6		%	1.1		%

Net (Loss) Income per Share (Tables)

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Summary of denominators for the computation of basic and diluted net income (loss) per share

The following table sets forth the calculation of basic and diluted net (loss) income per share:



	Three Months Ended September 30,					Nine Months Ended September 30,
	2017			2016		2017			2016
	(In millions, except net income per share)
Numerator:
Net (loss) income	$	(97	)	$	42	$	(250	)	$	99
Denominator:
Denominator for basic net (loss) income per share	57			56		56			55
Effect of dilutive securities:
1.125% Warrants ⁽¹⁾	—			—		—			1
Denominator for diluted net (loss) income per share	57			56		56			56

Net (loss) income per share: ⁽²⁾
Basic	$	(1.70	)	$	0.77	$	(4.44	)	$	1.79
Diluted	$	(1.70	)	$	0.76	$	(4.44	)	$	1.77

Potentially dilutive common shares excluded from calculations:
1.125% Warrants⁽¹⁾	2			—		2			—
1.625% Notes⁽¹⁾	1			—		—			—

______________________________

(1)


(2)	Source data for calculations in thousands.

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2017

Fair Value Disclosures [Abstract]

Fair value of assets measured on recurring basis

Our financial instruments measured at fair value on a recurring basis at September 30, 2017, were as follows:



	Total		Quoted Market Prices (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	(In millions)
Corporate debt securities	$	1,162	$	—	$	1,162	$	—
Government-sponsored enterprise securities (GSEs)	220		220		—		—
Municipal securities	131		—		131		—
Asset-backed securities	125		—		125		—
U.S. treasury notes	121		121		—		—
Certificates of deposit	28		—		28		—
Subtotal - current investments	1,787		341		1,446		—
Corporate debt securities	229		—		229		—
U.S. treasury notes	97		97		—		—
Subtotal - current restricted investments	326		97		229		—
1.125% Call Option derivative asset	425		—		—		425
Total assets	$	2,538	$	438	$	1,675	$	425

1.125% Conversion Option derivative liability	$	425	$	—	$	—	$	425
Total liabilities	$	425	$	—	$	—	$	425

Our financial instruments measured at fair value on a recurring basis at December 31, 2016, were as follows:



	Total		Quoted Market Prices (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	(In millions)
Corporate debt securities	$	1,179	$	—	$	1,179	$	—
GSEs	231		231		—		—
Municipal securities	142		—		142		—
Asset-backed securities	69		—		69		—
U.S. treasury notes	84		84		—		—
Certificates of deposit	53		—		53		—
Subtotal - current investments	1,758		315		1,443		—
1.125% Call Option derivative asset	267		—		—		267
Total assets	$	2,025	$	315	$	1,443	$	267

1.125% Conversion Option derivative liability	$	267	$	—	$	—	$	267
Total liabilities	$	267	$	—	$	—	$	267

Schedule of fair value, asset and liabilities measured on recurring basis - disclosure only



	September 30, 2017				December 31, 2016
	Carrying Value		Fair Value		Carrying Value		Fair Value
	(In millions)
5.375% Notes	$	692	$	726	$	691	$	714
1.125% Convertible Notes	489		927		471		792
4.875% Notes	325		324		—		—
Credit Facility	300		300		—		—
1.625% Convertible Notes	292		373		284		344
	$	2,098	$	2,650	$	1,446	$	1,850

Investments (Tables)

9 Months Ended

Sep. 30, 2017

Investments, Debt and Equity Securities [Abstract]

Investments

The following tables summarize our investments as of the dates indicated:



	September 30, 2017
	Amortized		Gross Unrealized				Estimated Fair
	Cost		Gains		Losses		Value
	(In millions)
Corporate debt securities	$	1,162	$	1	$	1	$	1,162
GSEs	221		—		1		220
Municipal securities	132		—		1		131
Asset-backed securities	125		—		—		125
U.S. treasury notes	121		—		—		121
Certificates of deposit	28		—		—		28
Subtotal - current investments	1,789		1		3		1,787
Corporate debt securities	229		—		—		229
U.S. treasury notes	97		—		—		97
Subtotal - current restricted investments	326		—		—		326
	$	2,115	$	1	$	3	$	2,113



	December 31, 2016
	Amortized		Gross Unrealized				Estimated Fair
	Cost		Gains		Losses		Value
	(In millions)
Corporate debt securities	$	1,180	$	1	$	2	$	1,179
GSEs	232		—		1		231
Municipal securities	143		—		1		142
Asset-backed securities	69		—		—		69
U.S. treasury notes	84		—		—		84
Certificates of deposit	53		—		—		53
	$	1,761	$	1	$	4	$	1,758

Schedule of available for sale securities continuous unrealized loss position



	In a Continuous Loss Position for Less than 12 Months					In a Continuous Loss Position for 12 Months or More
	Estimated Fair Value		Unrealized Losses		Total Number of Positions	Estimated Fair Value		Unrealized Losses		Total Number of Positions
	(Dollars in millions)
Corporate debt securities	$	783	$	1	314	$	—	$	—	—
GSEs	—		—		—	58		1		20
Municipal securities	97		1		116	—		—		—
	$	880	$	2	430	$	58	$	1	20



	In a Continuous Loss Position for Less than 12 Months					In a Continuous Loss Position for 12 Months or More
	Estimated Fair Value		Unrealized Losses		Total Number of Positions	Estimated Fair Value		Unrealized Losses		Total Number of Positions
	(Dollars in millions)
Corporate debt securities	$	542	$	2	378	$	—	$	—	—
GSEs	198		1		73	—		—		—
Municipal securities	101		1		129	—		—		—
	$	841	$	4	580	$	—	$	—	—

Contractual maturities of investments

The contractual maturities of our held-to-maturity restricted investments, which are carried at amortized cost, which approximates fair value, as of September 30, 2017 are summarized below:



	Amortized Cost		Estimated Fair Value
	(In millions)
Due in one year or less	$	100	$	100
Due after one year through five years	17		17
	$	117	$	117

The contractual maturities of our available-for-sale investments as of September 30, 2017 are summarized below:



	Amortized Cost		Estimated Fair Value
	(In millions)
Due in one year or less	$	1,154	$	1,153
Due after one year through five years	944		943
Due after five years through ten years	17		17
	$	2,115	$	2,113

Medical Claims and Benefits Payable (Tables)

9 Months Ended

Sep. 30, 2017

Other Liabilities Disclosure [Abstract]

Schedule of liability for unpaid claims and claims adjustment expense



	September 30, 2017		December 31, 2016
	(In millions)
Fee-for-service claims incurred but not paid (IBNP)	$	1,681	$	1,352
Pharmacy payable	125		112
Capitation payable	57		37
Other	615		428
	$	2,478	$	1,929

Components of change in medical claims and benefits payable



	Nine Months Ended September 30,
	2017			2016
	(Dollars in millions)
Medical claims and benefits payable, beginning balance	$	1,929		$	1,685
Components of medical care costs related to:
Current period	12,813			11,120
Prior periods	9			(190		)
Total medical care costs	12,822			10,930

Change in non-risk provider payables	172			70

Payments for medical care costs related to:
Current period	10,944			9,536
Prior periods	1,501			1,278
Total paid	12,445			10,814
Medical claims and benefits payable, ending balance	$	2,478		$	1,871
Benefit from prior period as a percentage of:
Balance at beginning of period	(0.5		)%	11.3		%
Premium revenue, trailing twelve months	—		%	1.2		%
Medical care costs, trailing twelve months	(0.1		)%	1.3		%

Debt (Tables)

9 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Long term debt

The following table summarizes our outstanding debt obligations and their classification in the accompanying consolidated balance sheets (in millions):



	September 30, 2017			December 31, 2016
Current portion of long-term debt:
1.125% Convertible Notes, net of unamortized discount	$	494		$	477
1.625% Convertible Notes, net of unamortized premium and discount	293			—
Lease financing obligations	1			1
Debt issuance costs	(6		)	(6		)
	782			472
Non-current portion of long-term debt:
5.375% Notes	700			700
4.875% Notes	330			—
Credit Facility	300			—
1.625% Convertible Notes, net of unamortized premium and discount	—			286
Debt issuance costs	(13		)	(11		)
	1,317			975
Lease financing obligations	198			198
	$	2,297		$	1,645

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644

+ Details

Derivatives (Tables)

9 Months Ended

Sep. 30, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value

The following table summarizes the fair values and the presentation of our derivative financial instruments (defined and discussed individually below) in the accompanying consolidated balance sheets:



	Balance Sheet Location	September 30, 2017		December 31, 2016
		(In millions)
Derivative asset:
1.125% Call Option	Current assets: Derivative asset	$	425	$	267
Derivative liability:
1.125% Conversion Option	Current liabilities: Derivative liability	$	425	$	267

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2017

Stockholders' Equity Note [Abstract]

Restricted share activity

Restricted stock awards (RSAs), performance stock awards (PSAs) and performance stock units (PSUs) activity for the nine months ended September 30, 2017 is summarized below:



	Restricted Stock Awards		Performance Stock Awards		Performance Stock Units		Total		Weighted Average Grant Date Fair Value
Unvested balance, December 31, 2016	577,244		345,656		—		922,900		$	58.15
Granted	386,273		—		231,100		617,373		57.16
Vested	(391,680	)	(260,894	)	(139,272	)	(791,846	)	57.78
Forfeited	(69,346	)	—		—		(69,346	)	54.37
Unvested balance, September 30, 2017	502,491		84,762		91,828		679,081		57.61

Impairment Losses (Tables)

9 Months Ended

Sep. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Balances of goodwill



	Health Plans			Molina Medicaid Solutions			Other			Total
	(In millions)
Historical goodwill	$	445		$	71		$	162		$	678
Accumulated impairment losses at December 31, 2016	(58		)	—			—			(58		)
Balance, December 31, 2016	387			71			162			620
Impairment losses, three months ended June 30, 2017	—			—			(61		)	(61		)
Impairment losses, three months ended September 30, 2017	—			(28		)	(101		)	(129		)
Balance, September 30, 2017	$	387		$	43		$	—		$	430
Accumulated impairment losses at September 30, 2017	$	58		$	28		$	162		$	248

Restructuring and Separation Costs (Tables)

9 Months Ended

Sep. 30, 2017

Restructuring and Related Activities [Abstract]

Expected Costs



Estimated Costs Expected to be Incurred by Reportable Segment	Health Plans	Molina Medicaid Solutions	Other	Total
	(In millions)
Termination benefits	$30 to $35	—	$30 to $35	$60 to $70
Other restructuring costs	$40 to $45	$10	$110 to $115	$160 to $170
	$70 to $80	$10	$140 to $150	$220 to $240

Separation Costs



	Three Months Ended September 30, 2017
	Separation Costs - Former Executives		One-Time Termination Benefits		Other Restructuring Costs						Total
	Separation Costs - Former Executives		One-Time Termination Benefits		Write-offs of Long-lived Assets		Consulting Fees		Contract Termination Costs		Total
	(In millions)
Health Plans	$	—	$	27	$	6	$	—	$	—	$	33
Molina Medicaid Solutions	—		—		8		—		—		8
Other	—		23		35		16		3		77
	$	—	$	50	$	49	$	16	$	3	$	118



	Nine Months Ended September 30, 2017
	Separation Costs - Former Executives		One-Time Termination Benefits		Other Restructuring Costs						Total
	Separation Costs - Former Executives		One-Time Termination Benefits		Write-offs of Long-lived Assets		Consulting Fees		Contract Termination Costs		Total
	(In millions)
Health Plans	$	—	$	27	$	6	$	—	$	—	$	33
Molina Medicaid Solutions	—		—		8		—		—		8
Other	35		23		35		24		3		120
	$	35	$	50	$	49	$	24	$	3	$	161

Restructuring Reserve



	Separation Costs - Former Executives			One-Time Termination Benefits			Other Restructuring Costs			Total
	(In millions)
Accrued as of December 31, 2016	$	—		$	—		$	—		$	—
Charges	12			50			27			89
Cash payments	(1		)	(9		)	(14		)	(24		)
Accrued as of September 30, 2017	$	11		$	41		$	13		$	65

Segment Information (Tables)

9 Months Ended

Sep. 30, 2017

Segment Reporting [Abstract]

Operating segment information



	Health Plans			Molina Medicaid Solutions			Other			Consolidated
	Health Plans			Molina Medicaid Solutions			Other			Consolidated
	(In millions)
Three Months Ended September 30, 2017
Total revenue ⁽¹⁾	$	4,899		$	47		$	85		$	5,031
Gross margin	557			5			2			564
Impairment losses	—			(28		)	(101		)	(129		)
Restructuring and separation costs	(33		)	(8		)	(77		)	(118		)

Nine Months Ended September 30, 2017
Total revenue ⁽¹⁾	$	14,538		$	140		$	256		$	14,934
Gross margin	1,343			13			8			1,364
Impairment losses	—			(28		)	(173		)	(201		)
Restructuring and separation costs	(33		)	(8		)	(120		)	(161		)

Three Months Ended September 30, 2016
Total revenue ⁽¹⁾	$	4,412		$	48		$	86		$	4,546
Gross margin	443			6			8			457
Impairment losses	—			—			—			—
Restructuring and separation costs	—			—			—			—

Nine Months Ended September 30, 2016
Total revenue ⁽¹⁾	$	12,835		$	146		$	267		$	13,248
Gross margin	1,285			17			29			1,331
Impairment losses	—			—			—			—
Restructuring and separation costs	—			—			—			—

Total assets
September 30, 2017	$	7,031		$	233		$	1,690		$	8,954
December 31, 2016	5,897			267			1,285			7,449

Goodwill and intangible assets, net
September 30, 2017	$	488		$	43		$	—		$	531
December 31, 2016	513			72			175			760

______________________


(1)	Total revenue consists primarily of premium revenue, premium tax revenue and health insurer fee revenue for the Health Plans segment, and service revenue for the Molina Medicaid Solutions and Other segments. Inter-segment revenue is insignificant for all periods presented.

The following table reconciles gross margin by segment to consolidated income before income tax expense:



	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
	(In millions)
Gross margin:
Health Plans	$	557		$	443		$	1,343		$	1,285
Molina Medicaid Solutions	5			6			13			17
Other	2			8			8			29
Total gross margin	564			457			1,364			1,331
Add: other operating revenues ⁽¹⁾	124			222			379			625
Less: other operating expenses ⁽²⁾	(769		)	(561		)	(2,029		)	(1,644		)
Operating (loss) income	(81		)	118			(286		)	312
Other expenses, net	32			26			10			76
(Loss) income before income taxes	$	(113	)	$	92		$	(296	)	$	236

______________________


(1)	Other operating revenues include premium tax revenue, health insurer fee revenue, investment income and other revenue.


(2)	Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fee expenses, depreciation and amortization, impairment losses, and restructuring and separation costs.

Supplemental Condensed Consolidating Financial Information (Tables)

9 Months Ended

Sep. 30, 2017

Condensed Financial Information [Abstract]

Condensed Consolidating Statements of Income

CONDENSED CONSOLIDATING STATEMENTS OF INCOME



	Three Months Ended September 30, 2016
	Parent Guarantor			Other Guarantors			Non-Guarantors		Eliminations			Consolidated
	(In millions)
Revenue:
Total revenue	$	274		$	48		$	4,498	$	(274	)	$	4,546
Expenses:
Medical care costs	19			—			3,730		(1		)	3,748
Cost of service revenue	—			42			77		—			119
General and administrative expenses	223			(4		)	397		(273		)	343
Premium tax expenses	—			—			127		—			127
Health insurer fee expenses	—			—			55		—			55
Depreciation and amortization	25			2			9		—			36
Total operating expenses	267			40			4,395		(274		)	4,428
Operating income	7			8			103		—			118
Interest expense	26			—			—		—			26
(Loss) income before income taxes	(19		)	8			103		—			92
Income tax expense	4			—			46		—			50
Net (loss) income before equity in net earnings of subsidiaries	(23		)	8			57		—			42
Equity in net earnings of subsidiaries	65			—			—		(65		)	—
Net income	$	42		$	8		$	57	$	(65	)	$	42

CONDENSED CONSOLIDATING STATEMENTS OF OPERATIONS



	Three Months Ended September 30, 2017
	Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations			Consolidated
	(In millions)
Revenue:
Total revenue	$	380		$	47		$	4,983		$	(379	)	$	5,031
Expenses:
Medical care costs	3			—			4,217			—			4,220
Cost of service revenue	—			42			81			—			123
General and administrative expenses	244			(1		)	519			(379		)	383
Premium tax expenses	—			—			106			—			106
Depreciation and amortization	23			1			9			—			33
Impairment losses	—			28			101			—			129
Restructuring and separation costs	77			8			33			—			118
Total operating expenses	347			78			5,066			(379		)	5,112
Operating income (loss)	33			(31		)	(83		)	—			(81		)
Interest expense	32			—			—			—			32
Income (loss) before income taxes	1			(31		)	(83		)	—			(113		)
Income tax expense (benefit)	9			(10		)	(15		)	—			(16		)
Net loss before equity in net losses of subsidiaries	(8		)	(21		)	(68		)	—			(97		)
Equity in net losses of subsidiaries	(89		)	(77		)	—			166			—
Net loss	$	(97	)	$	(98	)	$	(68	)	$	166		$	(97	)

CONDENSED CONSOLIDATING STATEMENTS OF INCOME



	Nine Months Ended September 30, 2016
	Parent Guarantor			Other Guarantors			Non-Guarantors		Eliminations			Consolidated
	(In millions)
Revenue:
Total revenue	$	786		$	147		$	13,099	$	(784	)	$	13,248
Expenses:
Medical care costs	50			—			10,881		(1		)	10,930
Cost of service revenue	—			130			232		—			362
General and administrative expenses	659			5			1,153		(783		)	1,034
Premium tax expenses	—			—			345		—			345
Health insurer fee expenses	—			—			163		—			163
Depreciation and amortization	70			5			27		—			102
Total operating expenses	779			140			12,801		(784		)	12,936
Operating income	7			7			298		—			312
Interest expense	76			—			—		—			76
(Loss) income before income taxes	(69		)	7			298		—			236
Income tax (benefit) expense	(24		)	(1		)	162		—			137
Net (loss) income before equity in earnings of subsidiaries	(45		)	8			136		—			99
Equity in net earnings of subsidiaries	144			3			—		(147		)	—
Net income	$	99		$	11		$	136	$	(147	)	$	99

CONDENSED CONSOLIDATING STATEMENTS OF OPERATIONS



	Nine Months Ended September 30, 2017
	Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations			Consolidated
	(In millions)
Revenue:
Total revenue	$	1,010		$	146		$	14,792		$	(1,014	)	$	14,934
Expenses:
Medical care costs	10			—			12,812			—			12,822
Cost of service revenue	—			127			242			—			369
General and administrative expenses	799			13			1,429			(1,014		)	1,227
Premium tax expenses	—			—			331			—			331
Depreciation and amortization	75			1			33			—			109
Impairment losses	—			28			173			—			201
Restructuring and separation costs	120			8			33			—			161
Total operating expenses	1,004			177			15,053			(1,014		)	15,220
Operating income (loss)	6			(31		)	(261		)	—			(286		)
Interest expense	85			—			—			—			85
Other income, net	(75		)	—			—			—			(75		)
Loss before income taxes	(4		)	(31		)	(261		)	—			(296		)
Income tax expense (benefit)	26			(10		)	(62		)	—			(46		)
Net loss before equity in net losses of subsidiaries	(30		)	(21		)	(199		)	—			(250		)
Equity in net losses of subsidiaries	(220		)	(143		)	—			363			—
Net loss	$	(250	)	$	(164	)	$	(199	)	$	363		$	(250	)

Condensed Consolidating Statements of Comprehensive Income

CONDENSED CONSOLIDATING STATEMENTS OF COMPREHENSIVE INCOME



	Three Months Ended September 30, 2016
	Parent Guarantor			Other Guarantors		Non-Guarantors			Eliminations			Consolidated

	(In millions)
Net income	$	42		$	8	$	57		$	(65	)	$	42
Other comprehensive loss, net of tax	(1		)	—		(1		)	1			(1		)
Comprehensive income	$	41		$	8	$	56		$	(64	)	$	41

CONDENSED CONSOLIDATING STATEMENTS OF COMPREHENSIVE LOSS



	Nine Months Ended September 30, 2017
	Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations			Consolidated
	(In millions)
Net loss	$	(250	)	$	(164	)	$	(199	)	$	363		$	(250	)
Other comprehensive income, net of tax	1			—			1			(1		)	1
Comprehensive loss	$	(249	)	$	(164	)	$	(198	)	$	362		$	(249	)

CONDENSED CONSOLIDATING STATEMENTS OF COMPREHENSIVE INCOME



	Nine Months Ended September 30, 2016
	Parent Guarantor		Other Guarantors		Non-Guarantors		Eliminations			Consolidated
	(In millions)
Net income	$	99	$	11	$	136	$	(147	)	$	99
Other comprehensive income, net of tax	7		—		6		(6		)	7
Comprehensive income	$	106	$	11	$	142	$	(153	)	$	106

CONDENSED CONSOLIDATING STATEMENTS OF COMPREHENSIVE LOSS



	Three Months Ended September 30, 2017
	Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations		Consolidated
	(In millions)
Net loss	$	(97	)	$	(98	)	$	(68	)	$	166	$	(97	)
Other comprehensive loss, net of tax	—			—			—			—		—
Comprehensive loss	$	(97	)	$	(98	)	$	(68	)	$	166	$	(97	)

Condensed Consolidating Balance Sheets

CONDENSED CONSOLIDATING BALANCE SHEETS



	September 30, 2017
	Parent Guarantor		Other Guarantors			Non-Guarantors			Eliminations			Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	356	$	58		$	3,520		$	—		$	3,934
Investments	35		—			1,752			—			1,787
Restricted investments	326		—			—			—			326
Receivables	2		25			975			—			1,002
Income taxes refundable	2		—			58			—			60
Due from (to) affiliates	203		(5		)	(198		)	—			—
Prepaid expenses and other current assets	65		20			89			—			174
Derivative asset	425		—			—			—			425
Total current assets	1,414		98			6,196			—			7,708
Property, equipment, and capitalized software, net	261		37			99			—			397
Deferred contract costs	—		97			—			—			97
Goodwill and intangible assets, net	55		43			433			—			531
Restricted investments	—		—			117			—			117
Investment in subsidiaries, net	2,625		95			—			(2,720		)	—
Deferred income taxes	10		—			96			(44		)	62
Other assets	50		2			6			(16		)	42
	$	4,415	$	372		$	6,947		$	(2,780	)	$	8,954

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Medical claims and benefits payable	$	—	$	—		$	2,478		$	—		$	2,478
Amounts due government agencies	—		—			1,324			—			1,324
Accounts payable and accrued liabilities	227		40			218			—			485
Deferred revenue	—		52			416			—			468
Current portion of long-term debt	782		—			—			—			782
Derivative liability	425		—			—			—			425
Total current liabilities	1,434		92			4,436			—			5,962
Long-term debt	1,515		—			16			(16		)	1,515
Deferred income taxes	12		32			—			(44		)	—
Other long-term liabilities	25		1			22			—			48
Total liabilities	2,986		125			4,474			(60		)	7,525
Total stockholders’ equity	1,429		247			2,473			(2,720		)	1,429
	$	4,415	$	372		$	6,947		$	(2,780	)	$	8,954

CONDENSED CONSOLIDATING BALANCE SHEETS



	December 31, 2016
	Parent Guarantor		Other Guarantors			Non-Guarantors			Eliminations			Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	86	$	6		$	2,727		$	—		$	2,819
Investments	178		—			1,580			—			1,758
Receivables	2		34			938			—			974
Income tax refundable	17		4			18			—			39
Due from (to) affiliates	104		(5		)	(99		)	—			—
Prepaid expenses and other current assets	58		30			43			—			131
Derivative asset	267		—			—			—			267
Total current assets	712		69			5,207			—			5,988
Property, equipment, and capitalized software, net	301		46			107			—			454
Deferred contract costs	—		86			—			—			86
Goodwill and intangible assets, net	58		73			629			—			760
Restricted investments	—		—			110			—			110
Investment in subsidiaries, net	2,609		246			—			(2,855		)	—
Deferred income taxes	10		—			—			—			10
Other assets	48		3			6			(16		)	41
	$	3,738	$	523		$	6,059		$	(2,871	)	$	7,449

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Medical claims and benefits payable	$	1	$	—		$	1,928		$	—		$	1,929
Amounts due government agencies	—		—			1,202			—			1,202
Accounts payable and accrued liabilities	146		34			205			—			385
Deferred revenue	—		40			275			—			315
Current portion of long-term debt	472		—			—			—			472
Derivative liability	267		—			—			—			267
Total current liabilities	886		74			3,610			—			4,570
Long-term debt	1,173		—			16			(16		)	1,173
Deferred income taxes	11		39			(35		)	—			15
Other long-term liabilities	19		1			22			—			42
Total liabilities	2,089		114			3,613			(16		)	5,800
Total stockholders’ equity	1,649		409			2,446			(2,855		)	1,649
	$	3,738	$	523		$	6,059		$	(2,871	)	$	7,449

Condensed Consolidating Statements of Cash Flows

CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS



	Nine Months Ended September 30, 2017
	Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations		Consolidated
	(In millions)
Operating activities:
Net cash provided by operating activities	$	215		$	81		$	661		$	—	$	957
Investing activities:
Purchases of investments	(333		)	—			(1,563		)	—		(1,896		)
Proceeds from sales and maturities of investments	150			—			1,388			—		1,538
Purchases of property, equipment and capitalized software	(67		)	(10		)	(8		)	—		(85		)
Increase in restricted investments held-to-maturity	—			—			(10		)	—		(10		)
Capital contributions to/from subsidiaries	(363		)	2			361			—		—
Dividends to/from subsidiaries	136			—			(136		)	—		—
Change in amounts due to/from affiliates	(100		)	—			100			—		—
Other, net	—			(21		)	—			—		(21		)
Net cash (used in) provided by investing activities	(577		)	(29		)	132			—		(474		)
Financing activities:
Proceeds from senior notes offering, net of issuance costs	325			—			—			—		325
Proceeds from borrowings under credit facility	300			—			—			—		300
Proceeds from employee stock plans	11			—			—			—		11
Other, net	(4		)	—			—			—		(4		)
Net cash provided by financing activities	632			—			—			—		632
Net increase in cash and cash equivalents	270			52			793			—		1,115
Cash and cash equivalents at beginning of period	86			6			2,727			—		2,819
Cash and cash equivalents at end of period	$	356		$	58		$	3,520		$	—	$	3,934

CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS



	Nine Months Ended September 30, 2016
	Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations		Consolidated
	(In millions)
Operating activities:
Net cash provided by operating activities	$	43		$	34		$	556		$	—	$	633
Investing activities:
Purchases of investments	(114		)	—			(1,330		)	—		(1,444		)
Proceeds from sales and maturities of investments	103			—			1,409			—		1,512
Purchases of property, equipment and capitalized software	(102		)	(23		)	(18		)	—		(143		)
Decrease in restricted investments held-to-maturity	—			—			4			—		4
Net cash paid in business combinations	—			(5		)	(43		)	—		(48		)
Capital contributions to/from subsidiaries	(221		)	7			214			—		—
Dividends to/from subsidiaries	50			—			(50		)	—		—
Change in amounts due to/from affiliates	(12		)	4			8			—		—
Other, net	6			(19		)	1			—		(12		)
Net cash (used in) provided by investing activities	(290		)	(36		)	195			—		(131		)
Financing activities:
Proceeds from employee stock plans	10			—			—			—		10
Other, net	2			—			(1		)	—		1
Net cash provided by (used in) financing activities	12			—			(1		)	—		11
Net (decrease) increase in cash and cash equivalents	(235		)	(2		)	750			—		513
Cash and cash equivalents at beginning of period	360			13			1,956			—		2,329
Cash and cash equivalents at end of period	$	125		$	11		$	2,706		$	—	$	2,842

Basis of Presentation (Details) member in Millions		1 Months Ended		3 Months Ended			9 Months Ended		12 Months Ended
Basis of Presentation (Details) member in Millions	Aug. 01, 2016 USD ($)	Aug. 31, 2017	Jun. 30, 2017	Sep. 30, 2017 USD ($) member State	Jun. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) member State Segment	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)	Mar. 31, 2017 USD ($)
Basis Of Presentation [Line Items]
Number of reportable segments (in segment) \| Segment							3
Goodwill impairment losses				$ 129,000,000	$ 61,000,000				$ 0
Impairment losses				$ 129,000,000		$ 0	$ 201,000,000	$ 0
Today's Options of New York, Inc. \| New York
Basis Of Presentation [Line Items]
Final purchase price of business acquisition	$ 38,000,000
Health Plans
Basis Of Presentation [Line Items]
Number of states in which entity operates (in state) \| State				12			12
Number of members eligible for the health care programs, approximately (in member) \| member				4.5			4.5
Minimum contract terms							3 years
Maximum contract terms							4 years
Goodwill impairment losses				$ 0	0
Impairment losses				0		$ 0	$ 0	$ 0
Medicare Acquisition terminated
Basis Of Presentation [Line Items]
Gain recognized on contract termination										$ 75,000,000
Molina Healthcare of Illinois, Inc.
Basis Of Presentation [Line Items]
Services contract term		4 years
Services contract renewal term		4 years
Mississippi Coordinated Access Network
Basis Of Presentation [Line Items]
Services contract renewal term			2 years
Molina Medicaid Solutions \| Subsidiaries
Basis Of Presentation [Line Items]
Goodwill impairment losses				28,000,000
Pathways \| Subsidiaries
Basis Of Presentation [Line Items]
Goodwill impairment losses				$ 101,000,000	59,000,000
Impairment losses					$ 72,000,000

Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Dec. 31, 2016
Schedule of Premium Revenue by Health Plan Type [Line Items]
Amounts due government agencies		$ 1,324		$ 1,202
Premium deficiency reserve		70	$ 100	30
Premium deficiency reserve, projected increase		55
Premium deficiency reserve, impact from change in computation		125
Medicaid Expansion
Schedule of Premium Revenue by Health Plan Type [Line Items]
Amounts due government agencies		82		244
Medical Premium Liability Due to Agency
Schedule of Premium Revenue by Health Plan Type [Line Items]
Medical premiums liability based on medical cost thresholds		119		$ 272
CMS Subsidies
Schedule of Premium Revenue by Health Plan Type [Line Items]
Accounts payable, related parties		$ 220
CMS Subsidies \| Forecast
Schedule of Premium Revenue by Health Plan Type [Line Items]
Operating expense	$ 85

Significant Accounting Policies - 3R Program Receivables (Payables) (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Risk adjustment payable, Current Benefit Year	$ (655)
Risk adjustment payable, Prior Benefit Year	0
Risk adjustment payable, Total	(655)	$ (522)
Reinsurance receivable, Current Benefit Year	0
Reinsurance receivable, Prior Benefit Year	10
Reinsurance receivable, Total	10	55
Risk corridor payable, Current Benefit Year	0
Risk corridor payable, Prior Benefit Year	0
Risk corridor payable, Total	0	(1)
Minimum MLR payable, Current Benefit Year	(27)
Minimum MLR payable, Prior Benefit Year	0
Minimum MLR payable, Total	$ (27)	$ (1)

Significant Accounting Policies - Quality Incentive Premium Revenue Recognized (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Schedule of Premium Revenue by Health Plan Type [Line Items]
Maximum available quality incentive premium - current period	$ 36	$ 33	$ 113	$ 114
Quality incentive premium revenue recognized in current period:
Earned current period	24	26	72	80
Earned prior periods	3	0	9	54
Total	$ 27	$ 26	$ 81	$ 134
Quality incentive premium revenue recognized as a percentage of total premium revenue	0.60%	0.60%	0.60%	1.10%
Minimum \| Select Health Plans
Schedule of Premium Revenue by Health Plan Type [Line Items]
Percentage of additional incremental revenue earned			1.00%
Maximum \| Select Health Plans
Schedule of Premium Revenue by Health Plan Type [Line Items]
Percentage of additional incremental revenue earned			3.00%

Net (Loss) Income per Share (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Numerator:
Net (loss) income	$ (97)	$ 42	$ (250)	$ 99
Denominator:
Denominator for basic net (loss) income per share (in shares)	57	56	56	55
Effect of dilutive securities:
1.125% Warrants (in shares)	0	0	0	1
Denominator for diluted net (loss) income per share (in shares)	57	56	56	56
Net (loss) income per share:
Basic (in dollars per share)	$ (1.70)	$ 0.77	$ (4.44)	$ 1.79
Diluted (in dollars per share)	$ (1.70)	$ 0.76	$ (4.44)	$ 1.77
Potentially dilutive common shares excluded from calculations:
Stated percentage of warrants	1.125%		1.125%
1.125% Warrants
Potentially dilutive common shares excluded from calculations:
Potentially dilutive common shares excluded from calculations	2	0	2	0
1.625% Notes
Potentially dilutive common shares excluded from calculations:
Potentially dilutive common shares excluded from calculations	1	0	0	0

Fair Value Measurements - Details of Long-Term Debt (Details) - USD ($) $ in Millions	Sep. 30, 2017	Jun. 06, 2017	Dec. 31, 2016	Nov. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
1.125% Convertible Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Percentage of contractual interest rate on Notes	1.125%
Senior Notes \| 5.375% Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Percentage of contractual interest rate on Notes	5.375%			5.375%
Senior Notes \| 4.875% Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Percentage of contractual interest rate on Notes	4.875%	4.875%
Convertible Notes \| 1.125% Convertible Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Percentage of contractual interest rate on Notes	1.125%		1.125%			1.125%
Convertible Notes \| 1.625% Convertible Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Percentage of contractual interest rate on Notes	1.625%				1.625%
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of debt	$ 2,098		$ 1,446
Carrying Value \| Senior Notes \| 5.375% Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of debt	692		691
Carrying Value \| Convertible Notes \| 1.125% Convertible Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of debt	489		471
Carrying Value \| Convertible Notes \| 4.875% Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of debt	325		0
Carrying Value \| Convertible Notes \| 1.625% Convertible Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of debt	292		284
Carrying Value \| Credit Facility
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of debt	300		0
Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of debt	2,650		1,850
Fair Value \| Senior Notes \| 5.375% Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of debt	726		714
Fair Value \| Convertible Notes \| 1.125% Convertible Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of debt	927		792
Fair Value \| Convertible Notes \| 4.875% Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of debt	324		0
Fair Value \| Convertible Notes \| 1.625% Convertible Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of debt	373		344
Fair Value \| Credit Facility
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of debt	$ 300		$ 0

Investments - Summary of Investments (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 2,115	$ 1,761
Gross Unrealized Gains	1	1
Gross Unrealized Losses	3	4
Estimated Fair Value	2,113	1,758
Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	229
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Estimated Fair Value	229
U.S. treasury notes
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	97
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Estimated Fair Value	97
Subtotal - current restricted investments
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	326
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Estimated Fair Value	326
Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,162	1,180
Gross Unrealized Gains	1	1
Gross Unrealized Losses	1	2
Estimated Fair Value	1,162	1,179
GSEs
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	221	232
Gross Unrealized Gains	0	0
Gross Unrealized Losses	1	1
Estimated Fair Value	220	231
Municipal securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	132	143
Gross Unrealized Gains	0	0
Gross Unrealized Losses	1	1
Estimated Fair Value	131	142
Asset-backed securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	125	69
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	125	69
U.S. treasury notes
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	121	84
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	121	84
Certificates of deposit
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	28	53
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	28	$ 53
Subtotal - current investments
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,789
Gross Unrealized Gains	1
Gross Unrealized Losses	3
Estimated Fair Value	$ 1,787

Investments - Contractual Maturities of Investments (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Amortized Cost
Due in one year or less	$ 1,154
Due after one year through five years	944
Due after five years through ten years	17
Amortized Cost	2,115	$ 1,761
Estimated Fair Value
Due in one year or less	1,153
Due after one year through five years	943
Due after five years through ten years	17
Total, Estimated Fair Value	$ 2,113

Investments - Available-for-Sale Investments (Details) $ in Millions	Sep. 30, 2017 USD ($) Security	Dec. 31, 2016 USD ($) Security
Schedule of Available-for-sale Securities [Line Items]
In a Continuous Loss Position for Less than 12 Months, Estimated Fair Value	$ 880	$ 841
In a Continuous Loss Position for Less than 12 Months, Unrealized Losses	$ 2	$ 4
In a Continuous Loss Position for Less than 12 Months, Number of Positions (in security) \| Security	430	580
In a Continuous Loss Position for 12 Months or More, Estimated Fair value	$ 58	$ 0
In a Continuous Loss Position for 12 Months or More, Unrealized Losses	$ 1	$ 0
In a Continuous Loss Position for 12 Months or More, Number of Positions (in security) \| Security	20	0
Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
In a Continuous Loss Position for Less than 12 Months, Estimated Fair Value	$ 783	$ 542
In a Continuous Loss Position for Less than 12 Months, Unrealized Losses	$ 1	$ 2
In a Continuous Loss Position for Less than 12 Months, Number of Positions (in security) \| Security	314	378
In a Continuous Loss Position for 12 Months or More, Estimated Fair value	$ 0	$ 0
In a Continuous Loss Position for 12 Months or More, Unrealized Losses	$ 0	$ 0
In a Continuous Loss Position for 12 Months or More, Number of Positions (in security) \| Security	0	0
GSEs
Schedule of Available-for-sale Securities [Line Items]
In a Continuous Loss Position for Less than 12 Months, Estimated Fair Value	$ 0	$ 198
In a Continuous Loss Position for Less than 12 Months, Unrealized Losses	$ 0	$ 1
In a Continuous Loss Position for Less than 12 Months, Number of Positions (in security) \| Security	0	73
In a Continuous Loss Position for 12 Months or More, Estimated Fair value	$ 58	$ 0
In a Continuous Loss Position for 12 Months or More, Unrealized Losses	$ 1	$ 0
In a Continuous Loss Position for 12 Months or More, Number of Positions (in security) \| Security	20	0
Municipal securities
Schedule of Available-for-sale Securities [Line Items]
In a Continuous Loss Position for Less than 12 Months, Estimated Fair Value	$ 97	$ 101
In a Continuous Loss Position for Less than 12 Months, Unrealized Losses	$ 1	$ 1
In a Continuous Loss Position for Less than 12 Months, Number of Positions (in security) \| Security	116	129
In a Continuous Loss Position for 12 Months or More, Estimated Fair value	$ 0	$ 0
In a Continuous Loss Position for 12 Months or More, Unrealized Losses	$ 0	$ 0
In a Continuous Loss Position for 12 Months or More, Number of Positions (in security) \| Security	0	0

Investments - Held to Maturity Investments (Details) $ in Millions	Sep. 30, 2017 USD ($)
Amortized Cost
Due in one year or less	$ 100
Due after one year through five years	17
Held-to-maturity Securities	117
Estimated Fair Value
Due in one year or less	100
Due after one year through five years	17
Estimated Fair Value, Total	$ 117

Medical Claims and Benefits Payable - Medical Claims and Future Benefits (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Other Liabilities Disclosure [Abstract]
Fee-for-service claims incurred but not paid (IBNP)	$ 1,681	$ 1,352
Pharmacy payable	125	112
Capitation payable	57	37
Other	615	428
Medical claims and benefits payable	$ 2,478	$ 1,929	$ 1,871	$ 1,685

Medical Claims and Benefits Payable - Additional Information (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Other Liabilities Disclosure [Abstract]
Non-risk provider payables	$ 403		$ 225
Reinsurance recoverables	16	$ 72
Liability for Claims and Claims Adjustment Expense [Line Items]
Expense (recovery) for prior period claims development	$ (9)	$ 190
Minimum
Liability for Claims and Claims Adjustment Expense [Line Items]
Percentage of IBNP not expected to be paid	8.00%
Maximum
Liability for Claims and Claims Adjustment Expense [Line Items]
Percentage of IBNP not expected to be paid	10.00%

Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Insurance Claims
Medical claims and benefits payable, beginning balance	$ 1,929	$ 1,685
Components of medical care costs related to:
Current period	12,813	11,120
Prior periods	9	(190)
Total medical care costs	12,822	10,930
Change in non-risk provider payables	172	70
Payments for medical care costs related to:
Current period	10,944	9,536
Prior periods	1,501	1,278
Total paid	12,445	10,814
Medical claims and benefits payable, ending balance	$ 2,478	$ 1,871
Benefit from prior period as a percentage of:
Balance at beginning of period	(0.50%)	11.30%
Premium revenue, trailing twelve months	0.00%	1.20%
Medical care costs, trailing twelve months	(0.10%)	1.30%

Debt - Schedule of Long-Term Debt (Details) - USD ($) $ in Millions	Sep. 30, 2017	Jun. 06, 2017	Dec. 31, 2016	Nov. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Current portion of long-term debt:
Lease financing obligations	$ 1		$ 1
Debt issuance costs	(6)		(6)
Current portion of long-term debt	782		472
Non-current portion of long-term debt:
Debt issuance costs	(13)		(11)
Senior notes	1,317		975
Lease financing obligations	198		198
Total debt	$ 2,297		1,645
1.125% Convertible Notes
Non-current portion of long-term debt:
Percentage of contractual interest rate on Notes	1.125%
1.125% Convertible Notes \| Convertible Notes
Current portion of long-term debt:
Debt net of unamortized discount	$ 494		$ 477
Non-current portion of long-term debt:
Percentage of contractual interest rate on Notes	1.125%		1.125%			1.125%
5.375% Notes \| Senior Notes
Non-current portion of long-term debt:
Debt net of unamortized debt discount	$ 700		$ 700
Percentage of contractual interest rate on Notes	5.375%			5.375%
4.875% Notes \| Senior Notes
Non-current portion of long-term debt:
Debt net of unamortized debt discount	$ 330		0
Percentage of contractual interest rate on Notes	4.875%	4.875%
Credit Facility \| Credit Facility
Non-current portion of long-term debt:
Debt net of unamortized debt discount	$ 300		0
1.625% Convertible Notes \| Convertible Notes
Current portion of long-term debt:
Debt net of unamortized discount	293		0
Non-current portion of long-term debt:
Debt net of unamortized debt discount	$ 0		$ 286
Percentage of contractual interest rate on Notes	1.625%				1.625%

Debt - Additional Information (Details) - USD ($)	9 Months Ended
Debt - Additional Information (Details) - USD ($)	Sep. 30, 2017	Jun. 06, 2017	Jan. 31, 2017	Dec. 31, 2016	Nov. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
1.125% Convertible Notes
Debt Instrument [Line Items]
Percentage of contractual interest rate on Notes	1.125%
Letter of Credit
Debt Instrument [Line Items]
Amount outstanding under Letter of Credit	$ 6,000,000
Letter of Credit \| Debt Commitment Letter
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 400,000,000
Senior Notes \| 4.875% Notes
Debt Instrument [Line Items]
Face amount of debts		$ 330,000,000
Percentage of contractual interest rate on Notes	4.875%	4.875%
Senior Notes \| 5.375% Notes
Debt Instrument [Line Items]
Percentage of contractual interest rate on Notes	5.375%				5.375%
Aggregate principal amount of notes outstanding	$ 700,000,000
Unsecured Debt \| Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 500,000,000
Current borrowing capacity	$ 194,000,000
Term of debt instrument	5 years
Amount outstanding under the Credit Facility	$ 300,000,000
Convertible Notes \| 1.125% Convertible Notes
Debt Instrument [Line Items]
Percentage of contractual interest rate on Notes	1.125%			1.125%			1.125%
Aggregate principal amount of notes outstanding	$ 550,000,000
Conversion price per share of common stock (in dollars per share)	$ 53.00
Convertible Notes \| 1.625% Convertible Notes
Debt Instrument [Line Items]
Percentage of contractual interest rate on Notes	1.625%					1.625%
Aggregate principal amount of notes outstanding	$ 302,000,000
Conversion price per share of common stock (in dollars per share)	$ 75.51

Derivatives (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
1.125% Convertible Notes
Derivative [Line Items]
Percentage of contractual interest rate on Notes	1.125%
1.125% Call Option
Derivative [Line Items]
Percentage of contractual interest rate on Call Option	1.125%
1.125% Conversion Option derivative liability
Derivative [Line Items]
Percentage of contractual interest rate on Call Option	1.125%
Current assets: Derivative asset \| 1.125% Call Option
Derivative [Line Items]
Derivative assets	$ 425	$ 267
Current liabilities: Derivative liability \| 1.125% Conversion Option derivative liability
Derivative [Line Items]
Derivative liabilities	$ 425	$ 267

Stockholders' Equity - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2013
Class of Stock [Line Items]
Decrease in stockholders' equity			$ 220,000,000
Net (loss) income	$ (97,000,000)	$ 42,000,000	(250,000,000)	$ 99,000,000
Employee stock transactions			$ 29,000,000
Number of warrants issued (in shares)						13,490,236
Warrant, strike price per share (usd per share)						$ 53.8475
Stated percentage of warrants	1.125%		1.125%
Employee stock compensation expense			$ 38,000,000	24,000,000
Unrecognized compensation expense	$ 27,000,000		$ 27,000,000
Unrecognized compensation forfeiture rate			4.50%
Restricted Stock Awards
Class of Stock [Line Items]
Total fair value of awards granted			$ 19,000,000	18,000,000
Total fair value of awards vested			$ 21,000,000	22,000,000
Accelerated vesting of awards (in shares)			133,957
Weighted average period for recognition			2 years 2 months
Performance Stock Awards
Class of Stock [Line Items]
Total fair value of awards granted			$ 0	15,000,000
Total fair value of awards vested			$ 15,000,000	$ 0
Accelerated vesting of awards (in shares)			153,574
Performance Stock Units
Class of Stock [Line Items]
Total fair value of awards granted			$ 16,000,000		$ 0
Total fair value of awards vested			$ 9,000,000		$ 0
Accelerated vesting of awards (in shares)			139,272
Weighted average period for recognition			1 year 11 months
Common Stock
Class of Stock [Line Items]
Number of common stock issued (in shares)			702,000

Stockholders' Equity - Share Activity (Details)	9 Months Ended
Stockholders' Equity - Share Activity (Details)	Sep. 30, 2017 $ / shares shares
Number of Shares
Beginning Balance (shares)	922,900
Granted (shares)	617,373
Vested (shares)	(791,846)
Forfeited (shares)	(69,346)
Ending Balance (shares)	679,081
Weighted Average Grant Date Fair Value
Begining Balance (usd per share) \| $ / shares	$ 58.15
Granted (usd per share) \| $ / shares	57.16
Vested (usd per share) \| $ / shares	57.78
Forfeited (usd per share) \| $ / shares	54.37
Ending Balance (usd per share) \| $ / shares	$ 57.61
Restricted Stock Awards
Number of Shares
Beginning Balance (shares)	577,244
Granted (shares)	386,273
Vested (shares)	(391,680)
Forfeited (shares)	(69,346)
Ending Balance (shares)	502,491
Performance Stock Awards
Number of Shares
Beginning Balance (shares)	345,656
Granted (shares)	0
Vested (shares)	(260,894)
Forfeited (shares)	0
Ending Balance (shares)	84,762
Performance Stock Units
Number of Shares
Beginning Balance (shares)	0
Granted (shares)	231,100
Vested (shares)	(139,272)
Forfeited (shares)	0
Ending Balance (shares)	91,828

Impairment Losses - Additional Information (Details) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2017	Jun. 30, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Impairment loss for the carrying amount of intangible assets		$ 11,000,000	$ 0
Goodwill impairment losses	$ 129,000,000	61,000,000	$ 0
Subsidiaries \| Molina Medicaid Solutions
Finite-Lived Intangible Assets [Line Items]
Goodwill impairment losses	28,000,000
Subsidiaries \| Pathways
Finite-Lived Intangible Assets [Line Items]
Goodwill impairment losses	$ 101,000,000	59,000,000
Subsidiaries \| Other subsidiary
Finite-Lived Intangible Assets [Line Items]
Goodwill impairment losses		$ 2,000,000

Impairment Losses - Goodwill Balances (Details) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2017	Jun. 30, 2017	Dec. 31, 2016	Sep. 30, 2017	Dec. 31, 2016
Goodwill
Historical goodwill					$ 678,000,000
Accumulated impairment losses				$ (248,000,000)	(58,000,000)
Goodwill	$ 430,000,000		$ 620,000,000	430,000,000	620,000,000
Goodwill
Impairment loss	(129,000,000)	$ (61,000,000)	0
Ending balance	430,000,000		620,000,000
Accumulated impairment losses				248,000,000	58,000,000
Health Plans
Goodwill
Historical goodwill					445,000,000
Accumulated impairment losses				(58,000,000)	(58,000,000)
Goodwill	387,000,000		387,000,000	387,000,000	387,000,000
Goodwill
Impairment loss	0	0
Ending balance	387,000,000		387,000,000
Accumulated impairment losses				58,000,000	58,000,000
Molina Medicaid Solutions
Goodwill
Historical goodwill					71,000,000
Accumulated impairment losses				(28,000,000)	0
Goodwill	43,000,000		71,000,000	43,000,000	71,000,000
Goodwill
Impairment loss	(28,000,000)	0
Ending balance	43,000,000		71,000,000
Accumulated impairment losses				28,000,000	0
Other segment
Goodwill
Historical goodwill					162,000,000
Accumulated impairment losses				(162,000,000)	0
Goodwill	0		162,000,000	0	162,000,000
Goodwill
Impairment loss		$ (61,000,000)
Ending balance	$ 0		$ 162,000,000
Accumulated impairment losses				$ 162,000,000	$ 0

Restructuring and Separation Costs - Expected Costs (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended		12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2018
Restructuring Cost and Reserve [Line Items]
Increase in expected restructuring costs		$ 50
Restructuring and separation costs		118	$ 0	$ 161	$ 0
Minimum
Estimated Costs Expected to be Incurred by Reportable Segment
Total restructuring costs		220		220
Maximum
Estimated Costs Expected to be Incurred by Reportable Segment
Total restructuring costs		240		240
Separation Costs - Former Executives
Restructuring Cost and Reserve [Line Items]
Restructuring and separation costs		0		35
Separation Costs - Former Executives \| Minimum
Estimated Costs Expected to be Incurred by Reportable Segment
Total restructuring costs		60		60
Separation Costs - Former Executives \| Maximum
Estimated Costs Expected to be Incurred by Reportable Segment
Total restructuring costs		70		70
Other Restructuring Costs \| Minimum
Estimated Costs Expected to be Incurred by Reportable Segment
Total restructuring costs		160		160
Other Restructuring Costs \| Maximum
Estimated Costs Expected to be Incurred by Reportable Segment
Total restructuring costs		170		170
Health Plans
Restructuring Cost and Reserve [Line Items]
Restructuring and separation costs		33	0	33	0
Health Plans \| Minimum
Estimated Costs Expected to be Incurred by Reportable Segment
Total restructuring costs		70		70
Health Plans \| Maximum
Estimated Costs Expected to be Incurred by Reportable Segment
Total restructuring costs		80		80
Health Plans \| Separation Costs - Former Executives
Restructuring Cost and Reserve [Line Items]
Restructuring and separation costs		0		0
Health Plans \| Separation Costs - Former Executives \| Minimum
Estimated Costs Expected to be Incurred by Reportable Segment
Total restructuring costs		30		30
Health Plans \| Separation Costs - Former Executives \| Maximum
Estimated Costs Expected to be Incurred by Reportable Segment
Total restructuring costs		35		35
Health Plans \| Other Restructuring Costs \| Minimum
Estimated Costs Expected to be Incurred by Reportable Segment
Total restructuring costs		40		40
Health Plans \| Other Restructuring Costs \| Maximum
Estimated Costs Expected to be Incurred by Reportable Segment
Total restructuring costs		45		45
Molina Medicaid Solutions
Restructuring Cost and Reserve [Line Items]
Restructuring and separation costs		8	0	8	0
Estimated Costs Expected to be Incurred by Reportable Segment
Total restructuring costs		10		10
Molina Medicaid Solutions \| Separation Costs - Former Executives
Restructuring Cost and Reserve [Line Items]
Restructuring and separation costs		0		0
Estimated Costs Expected to be Incurred by Reportable Segment
Total restructuring costs		0		0
Molina Medicaid Solutions \| Other Restructuring Costs
Estimated Costs Expected to be Incurred by Reportable Segment
Total restructuring costs		10		10
Other segment
Restructuring Cost and Reserve [Line Items]
Restructuring and separation costs		77	$ 0	120	$ 0
Other segment \| Minimum
Estimated Costs Expected to be Incurred by Reportable Segment
Total restructuring costs		140		140
Other segment \| Maximum
Estimated Costs Expected to be Incurred by Reportable Segment
Total restructuring costs		150		150
Other segment \| Separation Costs - Former Executives
Restructuring Cost and Reserve [Line Items]
Restructuring and separation costs		0		35
Other segment \| Separation Costs - Former Executives \| Minimum
Estimated Costs Expected to be Incurred by Reportable Segment
Total restructuring costs		30		30
Other segment \| Separation Costs - Former Executives \| Maximum
Estimated Costs Expected to be Incurred by Reportable Segment
Total restructuring costs		35		35
Other segment \| Other Restructuring Costs \| Minimum
Estimated Costs Expected to be Incurred by Reportable Segment
Total restructuring costs		110		110
Other segment \| Other Restructuring Costs \| Maximum
Estimated Costs Expected to be Incurred by Reportable Segment
Total restructuring costs		$ 115		$ 115
Forecast \| Minimum
Restructuring Cost and Reserve [Line Items]
Restructuring and separation costs	$ 70					$ 20
Forecast \| Maximum
Restructuring Cost and Reserve [Line Items]
Restructuring and separation costs	$ 90					$ 40

Restructuring and Separation Costs - Separation Costs (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring and separation costs	$ 118	$ 0	$ 161	$ 0
Charges			89
Separation Costs - Former Executives
Restructuring Cost and Reserve [Line Items]
Restructuring and separation costs	$ 0		35
Charges			12
Acceleration of share-based compensation			$ 23
Deferred termination fee \| Executive Officers
Restructuring Cost and Reserve [Line Items]
Cash awards as a percentage of base salary			400.00%
Deferred bonus \| Former CEO
Restructuring Cost and Reserve [Line Items]
Cash awards as a percentage of base salary			150.00%
Deferred bonus \| Former CFO
Restructuring Cost and Reserve [Line Items]
Cash awards as a percentage of base salary			125.00%

Restructuring and Separation Costs - Other Restructuring Costs (Details) $ in Millions	9 Months Ended
	Sep. 30, 2017 USD ($)
Restructuring Reserve
Accrued as of December 31, 2016	$ 0
Charges	89
Cash payments	(24)
Accrued as of September 30, 2017	65
Separation Costs - Former Executives
Restructuring Reserve
Accrued as of December 31, 2016	0
Charges	12
Cash payments	(1)
Accrued as of September 30, 2017	11
One-Time Termination Benefits
Restructuring Reserve
Accrued as of December 31, 2016	0
Charges	50
Cash payments	(9)
Accrued as of September 30, 2017	41
Other Restructuring Costs
Restructuring Reserve
Accrued as of December 31, 2016	0
Charges	27
Cash payments	(14)
Accrued as of September 30, 2017	$ 13

Segment Information - Additional Information (Details)	9 Months Ended
Segment Information - Additional Information (Details)	Sep. 30, 2017 Segment
Segment Reporting [Abstract]
Number of reportable segments (in segment)	3

Segment Information - Schedule of Operating Segment Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Segment Reporting Information [Line Items]
Total revenue	$ 5,031	$ 4,546	$ 14,934	$ 13,248
Gross margin	564	457	1,364	1,331
Impairment loss	(129)	0	(201)	0
Restructuring and separation costs	(118)	0	(161)	0
Total assets	8,954		8,954		$ 7,449
Goodwill and intangible assets, net	531		531		760
Health Plans
Segment Reporting Information [Line Items]
Total revenue	4,899	4,412	14,538	12,835
Gross margin	557	443	1,343	1,285
Impairment loss	0	0	0	0
Restructuring and separation costs	(33)	0	(33)	0
Total assets	7,031		7,031		5,897
Goodwill and intangible assets, net	488		488		513
Molina Medicaid Solutions
Segment Reporting Information [Line Items]
Total revenue	47	48	140	146
Gross margin	5	6	13	17
Impairment loss	(28)	0	(28)	0
Restructuring and separation costs	(8)	0	(8)	0
Total assets	233		233		267
Goodwill and intangible assets, net	43		43		72
Other
Segment Reporting Information [Line Items]
Total revenue	85	86	256	267
Gross margin	2	8	8	29
Impairment loss	(101)	0	(173)	0
Restructuring and separation costs	(77)	$ 0	(120)	$ 0
Total assets	1,690		1,690		1,285
Goodwill and intangible assets, net	$ 0		$ 0		$ 175

Segment Information - Reconciliation of Gross Margin to Consolidated Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Segment Reporting Information [Line Items]
Gross margin	$ 564	$ 457	$ 1,364	$ 1,331
Add: other operating revenues	5,031	4,546	14,934	13,248
Less: other operating expenses	(5,112)	(4,428)	(15,220)	(12,936)
Operating (loss) income	(81)	118	(286)	312
Other expenses, net	32	26	10	76
(Loss) income before income tax (benefit) expense	(113)	92	(296)	236
Health Plans
Segment Reporting Information [Line Items]
Gross margin	557	443	1,343	1,285
Add: other operating revenues	4,899	4,412	14,538	12,835
Molina Medicaid Solutions
Segment Reporting Information [Line Items]
Gross margin	5	6	13	17
Add: other operating revenues	47	48	140	146
Other
Segment Reporting Information [Line Items]
Gross margin	2	8	8	29
Add: other operating revenues	85	86	256	267
Operating Segments
Segment Reporting Information [Line Items]
Gross margin	564	457	1,364	1,331
Operating Segments \| Health Plans
Segment Reporting Information [Line Items]
Gross margin	557	443	1,343	1,285
Operating Segments \| Molina Medicaid Solutions
Segment Reporting Information [Line Items]
Gross margin	5	6	13	17
Operating Segments \| Other
Segment Reporting Information [Line Items]
Gross margin	2	8	8	29
Other operating
Segment Reporting Information [Line Items]
Add: other operating revenues	124	222	379	625
Less: other operating expenses	$ (769)	$ (561)	$ (2,029)	$ (1,644)

Commitments and Contingencies (Details) member in Thousands, $ in Millions		1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 01, 2015 plaintiff	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) member	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) member	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)
Entity Information [Line Items]
Net assets of subsidiaries subject to restrictions			$ 1,696		$ 1,696		$ 1,492
Aggregate statutory capital and surplus			1,828		1,828
Required minimum statutory capital surplus			1,113		1,113
Premium stabilization program, risk corridor, prior years			52		52
Premium stabilization program, risk corridor, current year			76		76
Premium revenue			4,777	$ 4,191	14,165	$ 12,215
Receivables			$ 1,002		$ 1,002		974
Illinois
Entity Information [Line Items]
Number of members served, approximately (in member) \| member			163		163
Puerto Rico
Entity Information [Line Items]
Number of members served, approximately (in member) \| member			306		306
Health Plans \| Illinois
Entity Information [Line Items]
Premium revenue					$ 447
Receivables			$ 220		220
Health Plans \| Puerto Rico
Entity Information [Line Items]
Premium revenue					553
The Rodriquez Litigation
Entity Information [Line Items]
Number of plaintiffs (in plaintiff) \| plaintiff	7
Rutherford County, Tennessee
Entity Information [Line Items]
Liabilities arising from contingencies, amount recognized		$ 3
Pathways Health and Community Support LLC
Entity Information [Line Items]
Liabilities arising from contingencies, amount recognized		$ 14		$ 14		$ 14
Parent Company
Entity Information [Line Items]
Restricted investments			$ 391		$ 391		$ 264

Related Party Transactions (Details)	Sep. 30, 2017
Pacific Healthcare IPA
Related Party Transaction [Line Items]
Ownership percentage	50.00%

Variable Interest Entities (VIEs) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Variable Interest Entity [Line Items]
Administrative fee revenue	$ 12	$ 13	$ 38	$ 40
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Amount paid for health care services	29	$ 31	89	$ 92
Total carrying amount of assets	20		20		$ 18
Total amount of liabilities	$ 24		$ 24		$ 18

Supplemental Condensed Consolidating Financial Information - Additional Information (Details)	Sep. 30, 2017	Nov. 30, 2015
Senior Notes \| 5.375% Notes
Condensed Financial Statements, Captions [Line Items]
Percentage of contractual interest rate on Notes	5.375%	5.375%

Supplemental Condensed Consolidating Financial Information - Statements of Operations (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue:
Total revenue	$ 5,031	$ 4,546	$ 14,934	$ 13,248
Expenses:
Medical care costs	4,220	3,748	12,822	10,930
Cost of service revenue	123	119	369	362
General and administrative expenses	383	343	1,227	1,034
Premium tax expenses	106	127	331	345
Health insurer fee expenses	0	55	0	163
Depreciation and amortization	33	36	109	102
Impairment losses	129	0	201	0
Restructuring and separation costs	118	0	161	0
Total operating expenses	5,112	4,428	15,220	12,936
Operating (loss) income	(81)	118	(286)	312
Interest expense	32	26	85	76
Other income, net	0	0	(75)	0
(Loss) income before income tax (benefit) expense	(113)	92	(296)	236
Income tax (benefit) expense	(16)	50	(46)	137
Net (loss) income before equity in earnings of subsidiaries	(97)	42	(250)	99
Equity in net earnings of subsidiaries	0	0	0	0
Net (loss) income	(97)	42	(250)	99
Eliminations
Revenue:
Total revenue	(379)	(274)	(1,014)	(784)
Expenses:
Medical care costs	0	(1)	0	(1)
Cost of service revenue	0	0	0	0
General and administrative expenses	(379)	(273)	(1,014)	(783)
Premium tax expenses	0	0	0	0
Health insurer fee expenses		0		0
Depreciation and amortization	0	0	0	0
Impairment losses	0		0
Restructuring and separation costs	0		0
Total operating expenses	(379)	(274)	(1,014)	(784)
Operating (loss) income	0	0	0	0
Interest expense	0	0	0	0
Other income, net			0
(Loss) income before income tax (benefit) expense	0	0	0	0
Income tax (benefit) expense	0	0	0	0
Net (loss) income before equity in earnings of subsidiaries	0	0	0	0
Equity in net earnings of subsidiaries	166	(65)	363	(147)
Net (loss) income	166	(65)	363	(147)
Parent Guarantor \| Reportable Legal Entities
Revenue:
Total revenue	380	274	1,010	786
Expenses:
Medical care costs	3	19	10	50
Cost of service revenue	0	0	0	0
General and administrative expenses	244	223	799	659
Premium tax expenses	0	0	0	0
Health insurer fee expenses		0		0
Depreciation and amortization	23	25	75	70
Impairment losses	0		0
Restructuring and separation costs	77		120
Total operating expenses	347	267	1,004	779
Operating (loss) income	33	7	6	7
Interest expense	32	26	85	76
Other income, net			(75)
(Loss) income before income tax (benefit) expense	1	(19)	(4)	(69)
Income tax (benefit) expense	9	4	26	(24)
Net (loss) income before equity in earnings of subsidiaries	(8)	(23)	(30)	(45)
Equity in net earnings of subsidiaries	(89)	65	(220)	144
Net (loss) income	(97)	42	(250)	99
Other Guarantors \| Reportable Legal Entities
Revenue:
Total revenue	47	48	146	147
Expenses:
Medical care costs	0	0	0	0
Cost of service revenue	42	42	127	130
General and administrative expenses	(1)	(4)	13	5
Premium tax expenses	0	0	0	0
Health insurer fee expenses		0		0
Depreciation and amortization	1	2	1	5
Impairment losses	28		28
Restructuring and separation costs	8		8
Total operating expenses	78	40	177	140
Operating (loss) income	(31)	8	(31)	7
Interest expense	0	0	0	0
Other income, net			0
(Loss) income before income tax (benefit) expense	(31)	8	(31)	7
Income tax (benefit) expense	(10)	0	(10)	(1)
Net (loss) income before equity in earnings of subsidiaries	(21)	8	(21)	8
Equity in net earnings of subsidiaries	(77)	0	(143)	3
Net (loss) income	(98)	8	(164)	11
Non-Guarantors \| Reportable Legal Entities
Revenue:
Total revenue	4,983	4,498	14,792	13,099
Expenses:
Medical care costs	4,217	3,730	12,812	10,881
Cost of service revenue	81	77	242	232
General and administrative expenses	519	397	1,429	1,153
Premium tax expenses	106	127	331	345
Health insurer fee expenses		55		163
Depreciation and amortization	9	9	33	27
Impairment losses	101		173
Restructuring and separation costs	33		33
Total operating expenses	5,066	4,395	15,053	12,801
Operating (loss) income	(83)	103	(261)	298
Interest expense	0	0	0	0
Other income, net			0
(Loss) income before income tax (benefit) expense	(83)	103	(261)	298
Income tax (benefit) expense	(15)	46	(62)	162
Net (loss) income before equity in earnings of subsidiaries	(68)	57	(199)	136
Equity in net earnings of subsidiaries	0	0	0	0
Net (loss) income	$ (68)	$ 57	$ (199)	$ 136

Supplemental Condensed Consolidating Financial Information - Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Condensed Statement of Income Captions [Line Items]
Net (loss) income	$ (97)	$ 42	$ (250)	$ 99
Other comprehensive income, net of tax	0	(1)	1	7
Comprehensive (loss) income	(97)	41	(249)	106
Eliminations
Condensed Statement of Income Captions [Line Items]
Net (loss) income	166	(65)	363	(147)
Other comprehensive income, net of tax	0	1	(1)	(6)
Comprehensive (loss) income	166	(64)	362	(153)
Parent Guarantor \| Reportable Legal Entities
Condensed Statement of Income Captions [Line Items]
Net (loss) income	(97)	42	(250)	99
Other comprehensive income, net of tax	0	(1)	1	7
Comprehensive (loss) income	(97)	41	(249)	106
Other Guarantors \| Reportable Legal Entities
Condensed Statement of Income Captions [Line Items]
Net (loss) income	(98)	8	(164)	11
Other comprehensive income, net of tax	0	0	0	0
Comprehensive (loss) income	(98)	8	(164)	11
Non-Guarantors \| Reportable Legal Entities
Condensed Statement of Income Captions [Line Items]
Net (loss) income	(68)	57	(199)	136
Other comprehensive income, net of tax	0	(1)	1	6
Comprehensive (loss) income	$ (68)	$ 56	$ (198)	$ 142

Supplemental Condensed Consolidating Financial Information - Balance Sheet (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 3,934	$ 2,819	$ 2,842	$ 2,329
Investments	1,787	1,758
Restricted investments	326	0
Receivables	1,002	974
Income taxes refundable	60	39
Due from (to) affiliates	0	0
Prepaid expenses and other current assets	174	131
Derivative asset	425	267
Total current assets	7,708	5,988
Property, equipment, and capitalized software, net	397	454
Deferred contract costs	97	86
Goodwill and intangible assets, net	531	760
Restricted investments	117	110
Investment in subsidiaries, net	0	0
Deferred income taxes	62	10
Other assets	42	41
Total assets	8,954	7,449
Current liabilities:
Medical claims and benefits payable	2,478	1,929	1,871	1,685
Amounts due government agencies	1,324	1,202
Accounts payable and accrued liabilities	485	385
Deferred revenue	468	315
Current portion of long-term debt	782	472
Derivative liability	425	267
Total current liabilities	5,962	4,570
Long-term debt	1,515	1,173
Deferred income taxes	0	15
Other long-term liabilities	48	42
Total liabilities	7,525	5,800
Total stockholders’ equity	1,429	1,649
Total liabilities and stockholders' equity	8,954	7,449
Eliminations
Current assets:
Cash and cash equivalents	0	0	0	0
Investments	0	0
Restricted investments	0
Receivables	0	0
Income taxes refundable	0	0
Due from (to) affiliates	0	0
Prepaid expenses and other current assets	0	0
Derivative asset	0	0
Total current assets	0	0
Property, equipment, and capitalized software, net	0	0
Deferred contract costs	0	0
Goodwill and intangible assets, net	0	0
Restricted investments	0	0
Investment in subsidiaries, net	(2,720)	(2,855)
Deferred income taxes	(44)	0
Other assets	(16)	(16)
Total assets	(2,780)	(2,871)
Current liabilities:
Medical claims and benefits payable	0	0
Amounts due government agencies	0	0
Accounts payable and accrued liabilities	0	0
Deferred revenue	0	0
Current portion of long-term debt	0	0
Derivative liability	0	0
Total current liabilities	0	0
Long-term debt	(16)	(16)
Deferred income taxes	(44)	0
Other long-term liabilities	0	0
Total liabilities	(60)	(16)
Total stockholders’ equity	(2,720)	(2,855)
Total liabilities and stockholders' equity	(2,780)	(2,871)
Parent Guarantor \| Reportable Legal Entities
Current assets:
Cash and cash equivalents	356	86	125	360
Investments	35	178
Restricted investments	326
Receivables	2	2
Income taxes refundable	2	17
Due from (to) affiliates	203	104
Prepaid expenses and other current assets	65	58
Derivative asset	425	267
Total current assets	1,414	712
Property, equipment, and capitalized software, net	261	301
Deferred contract costs	0	0
Goodwill and intangible assets, net	55	58
Restricted investments	0	0
Investment in subsidiaries, net	2,625	2,609
Deferred income taxes	10	10
Other assets	50	48
Total assets	4,415	3,738
Current liabilities:
Medical claims and benefits payable	0	1
Amounts due government agencies	0	0
Accounts payable and accrued liabilities	227	146
Deferred revenue	0	0
Current portion of long-term debt	782	472
Derivative liability	425	267
Total current liabilities	1,434	886
Long-term debt	1,515	1,173
Deferred income taxes	12	11
Other long-term liabilities	25	19
Total liabilities	2,986	2,089
Total stockholders’ equity	1,429	1,649
Total liabilities and stockholders' equity	4,415	3,738
Other Guarantors \| Reportable Legal Entities
Current assets:
Cash and cash equivalents	58	6	11	13
Investments	0	0
Restricted investments	0
Receivables	25	34
Income taxes refundable	0	4
Due from (to) affiliates	(5)	(5)
Prepaid expenses and other current assets	20	30
Derivative asset	0	0
Total current assets	98	69
Property, equipment, and capitalized software, net	37	46
Deferred contract costs	97	86
Goodwill and intangible assets, net	43	73
Restricted investments	0	0
Investment in subsidiaries, net	95	246
Deferred income taxes	0	0
Other assets	2	3
Total assets	372	523
Current liabilities:
Medical claims and benefits payable	0	0
Amounts due government agencies	0	0
Accounts payable and accrued liabilities	40	34
Deferred revenue	52	40
Current portion of long-term debt	0	0
Derivative liability	0	0
Total current liabilities	92	74
Long-term debt	0	0
Deferred income taxes	32	39
Other long-term liabilities	1	1
Total liabilities	125	114
Total stockholders’ equity	247	409
Total liabilities and stockholders' equity	372	523
Non-Guarantors \| Reportable Legal Entities
Current assets:
Cash and cash equivalents	3,520	2,727	$ 2,706	$ 1,956
Investments	1,752	1,580
Restricted investments	0
Receivables	975	938
Income taxes refundable	58	18
Due from (to) affiliates	(198)	(99)
Prepaid expenses and other current assets	89	43
Derivative asset	0	0
Total current assets	6,196	5,207
Property, equipment, and capitalized software, net	99	107
Deferred contract costs	0	0
Goodwill and intangible assets, net	433	629
Restricted investments	117	110
Investment in subsidiaries, net	0	0
Deferred income taxes	96	0
Other assets	6	6
Total assets	6,947	6,059
Current liabilities:
Medical claims and benefits payable	2,478	1,928
Amounts due government agencies	1,324	1,202
Accounts payable and accrued liabilities	218	205
Deferred revenue	416	275
Current portion of long-term debt	0	0
Derivative liability	0	0
Total current liabilities	4,436	3,610
Long-term debt	16	16
Deferred income taxes	0	(35)
Other long-term liabilities	22	22
Total liabilities	4,474	3,613
Total stockholders’ equity	2,473	2,446
Total liabilities and stockholders' equity	$ 6,947	$ 6,059

Supplemental Condensed Consolidating Financial Information - Cash Flows (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Operating activities:
Net cash provided by operating activities	$ 957	$ 633
Investing activities:
Purchases of investments	(1,896)	(1,444)
Proceeds from sales and maturities of investments	1,538	1,512
Purchases of property, equipment and capitalized software	(85)	(143)
(Increase) decrease in restricted investments held-to-maturity	(10)	4
Net cash paid in business combinations	0	(48)
Capital contributions to/from subsidiaries	0	0
Dividends to/from subsidiaries	0	0
Change in amounts due to/from affiliates	0	0
Other, net	(21)	(12)
Net cash used in investing activities	(474)	(131)
Financing activities:
Proceeds from senior notes offering, net of issuance costs	325
Proceeds from borrowings under credit facility	300	0
Proceeds from employee stock plans	11	10
Other, net	(4)	1
Net cash provided by financing activities	632	11
Net increase in cash and cash equivalents	1,115	513
Cash and cash equivalents at beginning of period	2,819	2,329
Cash and cash equivalents at end of period	3,934	2,842
Eliminations
Operating activities:
Net cash provided by operating activities	0	0
Investing activities:
Purchases of investments	0	0
Proceeds from sales and maturities of investments	0	0
Purchases of property, equipment and capitalized software	0	0
(Increase) decrease in restricted investments held-to-maturity	0	0
Net cash paid in business combinations		0
Capital contributions to/from subsidiaries	0	0
Dividends to/from subsidiaries	0	0
Change in amounts due to/from affiliates	0	0
Other, net	0	0
Net cash used in investing activities	0	0
Financing activities:
Proceeds from senior notes offering, net of issuance costs	0
Proceeds from borrowings under credit facility	0
Proceeds from employee stock plans	0	0
Other, net	0	0
Net cash provided by financing activities	0	0
Net increase in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Parent Guarantor \| Reportable Legal Entities
Operating activities:
Net cash provided by operating activities	215	43
Investing activities:
Purchases of investments	(333)	(114)
Proceeds from sales and maturities of investments	150	103
Purchases of property, equipment and capitalized software	(67)	(102)
(Increase) decrease in restricted investments held-to-maturity	0	0
Net cash paid in business combinations		0
Capital contributions to/from subsidiaries	(363)	(221)
Dividends to/from subsidiaries	136	50
Change in amounts due to/from affiliates	(100)	(12)
Other, net	0	6
Net cash used in investing activities	(577)	(290)
Financing activities:
Proceeds from senior notes offering, net of issuance costs	325
Proceeds from borrowings under credit facility	300
Proceeds from employee stock plans	11	10
Other, net	(4)	2
Net cash provided by financing activities	632	12
Net increase in cash and cash equivalents	270	(235)
Cash and cash equivalents at beginning of period	86	360
Cash and cash equivalents at end of period	356	125
Other Guarantors \| Reportable Legal Entities
Operating activities:
Net cash provided by operating activities	81	34
Investing activities:
Purchases of investments	0	0
Proceeds from sales and maturities of investments	0	0
Purchases of property, equipment and capitalized software	(10)	(23)
(Increase) decrease in restricted investments held-to-maturity	0	0
Net cash paid in business combinations		(5)
Capital contributions to/from subsidiaries	2	7
Dividends to/from subsidiaries	0	0
Change in amounts due to/from affiliates	0	4
Other, net	(21)	(19)
Net cash used in investing activities	(29)	(36)
Financing activities:
Proceeds from senior notes offering, net of issuance costs	0
Proceeds from borrowings under credit facility	0
Proceeds from employee stock plans	0	0
Other, net	0	0
Net cash provided by financing activities	0	0
Net increase in cash and cash equivalents	52	(2)
Cash and cash equivalents at beginning of period	6	13
Cash and cash equivalents at end of period	58	11
Non-Guarantors \| Reportable Legal Entities
Operating activities:
Net cash provided by operating activities	661	556
Investing activities:
Purchases of investments	(1,563)	(1,330)
Proceeds from sales and maturities of investments	1,388	1,409
Purchases of property, equipment and capitalized software	(8)	(18)
(Increase) decrease in restricted investments held-to-maturity	(10)	4
Net cash paid in business combinations		(43)
Capital contributions to/from subsidiaries	361	214
Dividends to/from subsidiaries	(136)	(50)
Change in amounts due to/from affiliates	100	8
Other, net	0	1
Net cash used in investing activities	132	195
Financing activities:
Proceeds from senior notes offering, net of issuance costs	0
Proceeds from borrowings under credit facility	0
Proceeds from employee stock plans	0	0
Other, net	0	(1)
Net cash provided by financing activities	0	(1)
Net increase in cash and cash equivalents	793	750
Cash and cash equivalents at beginning of period	2,727	1,956
Cash and cash equivalents at end of period	$ 3,520	$ 2,706

Fair Value Measurements - Fair Value of Financial Instruments on Recurring Basis (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
1.125% Call Option
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of contractual interest rate on Call Option	1.125%
1.125% Conversion Option derivative liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of contractual interest rate on Call Option	1.125%
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	$ 2,538	$ 2,025
Total liability measured at fair value on a recurring basis	425	267
Recurring \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	229
Recurring \| U.S. treasury notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	97
Recurring \| Subtotal - current restricted investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	326
Recurring \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	1,162	1,179
Recurring \| Government-sponsored enterprise securities (GSEs)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	220	231
Recurring \| Municipal securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	131	142
Recurring \| Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	125	69
Recurring \| U.S. treasury notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	121	84
Recurring \| Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	28	53
Recurring \| Subtotal - current investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	1,787	1,758
Recurring \| 1.125% Call Option derivative asset
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	425	267
Recurring \| 1.125% Conversion Option derivative liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
1.125% Conversion Option derivative liability	425	267
Recurring \| Quoted Market Prices (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	438	315
Total liability measured at fair value on a recurring basis	0	0
Recurring \| Quoted Market Prices (Level 1) \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	0
Recurring \| Quoted Market Prices (Level 1) \| U.S. treasury notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	97
Recurring \| Quoted Market Prices (Level 1) \| Subtotal - current restricted investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	97
Recurring \| Quoted Market Prices (Level 1) \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	0	0
Recurring \| Quoted Market Prices (Level 1) \| Government-sponsored enterprise securities (GSEs)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	220	231
Recurring \| Quoted Market Prices (Level 1) \| Municipal securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	0	0
Recurring \| Quoted Market Prices (Level 1) \| Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	0	0
Recurring \| Quoted Market Prices (Level 1) \| U.S. treasury notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	121	84
Recurring \| Quoted Market Prices (Level 1) \| Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	0	0
Recurring \| Quoted Market Prices (Level 1) \| Subtotal - current investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	341	315
Recurring \| Quoted Market Prices (Level 1) \| 1.125% Call Option derivative asset
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	0	0
Recurring \| Quoted Market Prices (Level 1) \| 1.125% Conversion Option derivative liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
1.125% Conversion Option derivative liability	0	0
Recurring \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	1,675	1,443
Total liability measured at fair value on a recurring basis	0	0
Recurring \| Significant Other Observable Inputs (Level 2) \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	229
Recurring \| Significant Other Observable Inputs (Level 2) \| U.S. treasury notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	0
Recurring \| Significant Other Observable Inputs (Level 2) \| Subtotal - current restricted investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	229
Recurring \| Significant Other Observable Inputs (Level 2) \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	1,162	1,179
Recurring \| Significant Other Observable Inputs (Level 2) \| Government-sponsored enterprise securities (GSEs)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	0	0
Recurring \| Significant Other Observable Inputs (Level 2) \| Municipal securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	131	142
Recurring \| Significant Other Observable Inputs (Level 2) \| Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	125	69
Recurring \| Significant Other Observable Inputs (Level 2) \| U.S. treasury notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	0	0
Recurring \| Significant Other Observable Inputs (Level 2) \| Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	28	53
Recurring \| Significant Other Observable Inputs (Level 2) \| Subtotal - current investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	1,446	1,443
Recurring \| Significant Other Observable Inputs (Level 2) \| 1.125% Call Option derivative asset
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	0	0
Recurring \| Significant Other Observable Inputs (Level 2) \| 1.125% Conversion Option derivative liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
1.125% Conversion Option derivative liability	0	0
Recurring \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	425	267
Total liability measured at fair value on a recurring basis	425	267
Recurring \| Significant Unobservable Inputs (Level 3) \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	0
Recurring \| Significant Unobservable Inputs (Level 3) \| U.S. treasury notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	0
Recurring \| Significant Unobservable Inputs (Level 3) \| Subtotal - current restricted investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	0
Recurring \| Significant Unobservable Inputs (Level 3) \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	0	0
Recurring \| Significant Unobservable Inputs (Level 3) \| Government-sponsored enterprise securities (GSEs)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	0	0
Recurring \| Significant Unobservable Inputs (Level 3) \| Municipal securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	0	0
Recurring \| Significant Unobservable Inputs (Level 3) \| Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	0	0
Recurring \| Significant Unobservable Inputs (Level 3) \| U.S. treasury notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	0	0
Recurring \| Significant Unobservable Inputs (Level 3) \| Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	0	0
Recurring \| Significant Unobservable Inputs (Level 3) \| Subtotal - current investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	0	0
Recurring \| Significant Unobservable Inputs (Level 3) \| 1.125% Call Option derivative asset
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value on a recurring basis	425	267
Recurring \| Significant Unobservable Inputs (Level 3) \| 1.125% Conversion Option derivative liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
1.125% Conversion Option derivative liability	$ 425	$ 267